<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002300.pub2" GROUP_ID="UPPERGI" ID="937999091416552868" MERGED_FROM="" MODIFIED="2010-10-12 15:39:28 +0200" MODIFIED_BY="Karin Dearness" REVIEW_NO="9" REVMAN_SUB_VERSION="5.0.25" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="14.0">
<COVER_SHEET MODIFIED="2010-10-12 15:39:28 +0200" MODIFIED_BY="Karin Dearness">
<TITLE>Cisapride treatment for gastro-oesophageal reflux in children</TITLE>
<CONTACT MODIFIED="2010-10-12 15:39:28 +0200" MODIFIED_BY="Karin Dearness"><PERSON ID="4798" ROLE="AUTHOR"><PREFIX>Ms.</PREFIX><FIRST_NAME>Suzanna</FIRST_NAME><LAST_NAME>MacLennan</LAST_NAME><POSITION>Staff Specialist in Neurology</POSITION><EMAIL_1>suzannamac@hotmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>Women's and Childrens Hospital</ORGANISATION><ADDRESS_1>72 King William Rd</ADDRESS_1><CITY>North Adelaide</CITY><ZIP>5006</ZIP><REGION>SA</REGION><COUNTRY CODE="AU">Australia</COUNTRY></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2010-10-12 15:39:28 +0200" MODIFIED_BY="Karin Dearness"><PERSON ID="4798" ROLE="AUTHOR"><PREFIX>Ms.</PREFIX><FIRST_NAME>Suzanna</FIRST_NAME><LAST_NAME>MacLennan</LAST_NAME><POSITION>Staff Specialist in Neurology</POSITION><EMAIL_1>suzannamac@hotmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>Women's and Childrens Hospital</ORGANISATION><ADDRESS_1>72 King William Rd</ADDRESS_1><CITY>North Adelaide</CITY><ZIP>5006</ZIP><REGION>SA</REGION><COUNTRY CODE="AU">Australia</COUNTRY></ADDRESS></PERSON><PERSON ID="11871" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Cristina</FIRST_NAME><LAST_NAME>Augood</LAST_NAME><POSITION>Research Fellow</POSITION><EMAIL_1>Cristina.Augood@lshtm.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Epidemiology &amp; Population Sciences,</DEPARTMENT><ORGANISATION>London School of Hygiene and Tropical Medicine</ORGANISATION><ADDRESS_1>EUREYE Study</ADDRESS_1><ADDRESS_2>Epidemiology Unit, Keppel Street</ADDRESS_2><CITY>London</CITY><ZIP>WC1E 7HT</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+4420 927 2108</PHONE_1><FAX_1>+4420 7580 6897</FAX_1></ADDRESS></PERSON><PERSON ID="4F7F860E82E26AA2017F61BBD177C06C" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Lucinda</FIRST_NAME><LAST_NAME>Cash-Gibson</LAST_NAME><POSITION>Research Assistant</POSITION><EMAIL_1>lucinda.cash-gibson@ich.ucl.ac.uk</EMAIL_1><EMAIL_2>cebch@ich.ucl.ac.uk</EMAIL_2><ADDRESS><DEPARTMENT>Centre for Evidence-Based Child Health</DEPARTMENT><ORGANISATION>UCL Institute of Child Health</ORGANISATION><ADDRESS_1>30 Guilford Street</ADDRESS_1><CITY>London</CITY><ZIP>WC1N 1EH</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 20 7905 2606</PHONE_1><FAX_1>+44 20 7905 2793</FAX_1></ADDRESS></PERSON><PERSON ID="7809" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Stuart</FIRST_NAME><LAST_NAME>Logan</LAST_NAME><POSITION>Director</POSITION><EMAIL_1>stuart.logan@pms.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Institute of Health Service Research</DEPARTMENT><ORGANISATION>Peninsula Medical School, Universities of Exeter &amp; Plymouth</ORGANISATION><ADDRESS_1>St Luke's Campus</ADDRESS_1><ADDRESS_2>Heavitree Road</ADDRESS_2><CITY>Exeter</CITY><ZIP>EX1 2LU</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1392 262991</PHONE_1><FAX_1>+44 1392 262964</FAX_1></ADDRESS></PERSON><PERSON ID="7504" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Ruth</FIRST_NAME><MIDDLE_INITIALS>E</MIDDLE_INITIALS><LAST_NAME>Gilbert</LAST_NAME><POSITION>Reader in Clinical Epidemiology</POSITION><EMAIL_1>r.gilbert@ich.ucl.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Centre for Paediatric Epidemiology and Biostatistics</DEPARTMENT><ORGANISATION>Institute of Child Health</ORGANISATION><ADDRESS_1>30 Guilford Street</ADDRESS_1><CITY>London</CITY><ZIP>WC1N 1EH</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 20 79052101</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2010-05-17 11:10:22 -0400" MODIFIED_BY="Karin Dearness">
<UP_TO_DATE>
<DATE DAY="5" MONTH="11" YEAR="2009"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="13" MONTH="2" YEAR="2009"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2000"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2003"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2010"/>
</DATES>
<WHATS_NEW MODIFIED="2010-10-12 09:37:47 -0400" MODIFIED_BY="Karin L Dearness">
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2010-10-12 09:37:47 -0400" MODIFIED_BY="Karin L Dearness">
<DATE DAY="12" MONTH="10" YEAR="2010"/>
<DESCRIPTION>
<P>Review no longer being updated due to stability of evidence.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2010-10-12 09:32:58 -0400" MODIFIED_BY="Karin L Dearness">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-10-12 09:32:58 -0400" MODIFIED_BY="Karin L Dearness">
<DATE DAY="26" MONTH="5" YEAR="2010"/>
<DESCRIPTION>
<P>Plain language summary revised</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2010-05-26 11:29:14 -0400" MODIFIED_BY="Karin L Dearness">
<DATE DAY="2" MONTH="3" YEAR="2010"/>
<DESCRIPTION>
<P>Updated, one new study included, conclusions not changed.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2010-05-26 11:29:13 -0400" MODIFIED_BY="Karin L Dearness">
<DATE DAY="5" MONTH="2" YEAR="2010"/>
<DESCRIPTION>
<P>Review declared stable.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-02-09 06:10:46 -0500" MODIFIED_BY="Cathy Bennett">
<DATE DAY="5" MONTH="11" YEAR="2009"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2009-06-10 07:16:46 -0400" MODIFIED_BY="Cathy Bennett">
<DATE DAY="13" MONTH="6" YEAR="2006"/>
<DESCRIPTION>
<P>Minor update new studies sought but none found</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2009-06-10 07:16:46 -0400" MODIFIED_BY="Cathy Bennett">
<DATE DAY="5" MONTH="4" YEAR="2002"/>
<DESCRIPTION>
<P>New studies found and included or excluded</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2010-01-12 01:33:14 -0500" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2010-01-12 01:33:14 -0500" MODIFIED_BY="[Empty name]">
<SOURCE>
<NAME>Systematic Reviews Training Unit</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2010-01-12 01:33:14 -0500" MODIFIED_BY="[Empty name]">
<NAME>Professor Stuart Logan was supported in this work by funding through PenCLAHRC, the NIHR Collaboration for Leadership in Applied Health Research and Care of the South West Peninsula</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2010-05-26 11:32:44 -0400" MODIFIED_BY="Karin L Dearness">
<SUMMARY MODIFIED="2010-05-26 11:32:44 -0400" MODIFIED_BY="Karin L Dearness">
<TITLE MODIFIED="2010-05-17 11:11:01 -0400" MODIFIED_BY="Karin L Dearness">Cisapride treatment for gastro-oesophageal reflux in young children</TITLE>
<SUMMARY_BODY MODIFIED="2010-05-26 11:32:44 -0400" MODIFIED_BY="Karin L Dearness">
<P>Gastro-oesophageal reflux is the movement of stomach contents back into the oesophagus. A ring of smooth muscle (sphincter) at the lower end of the oesophagus near the stomach usually prevents this regurgitation. Relaxation of the sphincter, ineffective clearance of food from the oesophagus into the stomach, and delayed emptying of the stomach can all contribute to reflux. The peak incidence of reflux is generally at around four months of age and resolves by one to two years. Parents may seek medical help for the reflux if they are anxious or find the symptoms of regurgitation, crying, irritability, vomiting and, gagging difficult to tolerate. Some young children experience associated respiratory problems of chronic cough, wheezing, hoarseness, recurring bronchitis, pneumonia, apnoea or breath holding; and back-arching, refusal to feed and sleep disturbance. Inflammation of the oesophagus may be evident with endoscopy or the child may fail to thrive and surgery may be required. Scintigraphy or sonography are used to monitor oesophageal motility.</P>
<P>Attention to the child&#8217;s position (by avoiding lying flat or a slumped seated position) and diet (thickened feeds, frequent small meals, non-prescription stabilisers such as Gaviscon) may be effective in reducing reflux. Medications include prokinetic drugs given before a meal to stimulate gut motility and acid-secretion inhibitors. Cisapride is a prokinetic drug used to improve symptoms and avoid serious complications of reflux. From this systematic review, we found no clear evidence of reduced symptoms of reflux with cisapride compared to placebo or no treatment. The parent or guardian of the child or the treating physician assessed the symptoms (regurgitation, crying, irritability, vomiting, gagging) at the end of treatment. Nine trials compared cisapride with placebo or no treatment, of which eight (262 participants) reported data on symptoms of gastro-oesophageal reflux in children aged between five days and five years. They were followed up for two weeks to eight weeks. </P>
<P>Investigations of reflux can include oesophageal pH monitoring for 18 to 24 hours to determine the number of episodes of pH &lt; 4, duration of the longest episode of pH &lt; 4 and the presence of sleep reflux. These pH measurements poorly correlate with symptoms and responses of a child to treatment.</P>
<P>Cisapride significantly reduced the percentage of time the pH &lt; 4 (reflux index) but not other measures of oesophageal pH monitoring</P>
<P>Fatal cardiac arrhythmia or sudden death have been associated with cisapride use in children and it is only used within restricted programmes under specialist supervision. One multicentre study of 134 children found no electrocardiographic QTc interval changes with cisapride.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2010-03-02 01:36:43 -0500" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2010-02-02 03:33:33 -0500" MODIFIED_BY="[Empty name]">
<P>Gastro-oesophageal reflux (GOR) is common and usually self-limiting in infants. Cisapride, a pro-kinetic agent, was commonly prescribed until reports of possible serious adverse events were associated with its use.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2010-01-21 08:16:48 -0500" MODIFIED_BY="[Empty name]">
<P>To determine the effectiveness of cisapride versus placebo or non-surgical treatments for symptoms of GOR.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2010-02-28 17:36:27 -0500" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Upper Gastrointestinal and Pancreatic Diseases Group Specialised Register and Central Register of Controlled Trials (CENTRAL), MEDLINE and EMBASE, reference lists of relevant review articles and searched in the Science Citation Index for all the trials identified. All searches were updated in February 2009.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2010-01-24 06:25:14 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials comparing oral cisapride therapy with placebo or other non-surgical treatments for children diagnosed with GOR were included. We excluded trials with a majority of participants less than 28 days of age.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2010-02-28 17:19:27 -0500" MODIFIED_BY="[Empty name]">
<P>Primary outcomes were a change in symptoms at the end of treatment, presence of adverse events, occurrence of clinical complications and weight gain. Secondary outcomes included physiological measures of GOR or histological evidence of oesophagitis. We dichotomised symptoms into 'same or worse' versus 'improved' and calculated summary odds ratios (OR). Continuous measures of GOR (for example reflux index) were summarised as a weighted mean difference. All outcomes were analysed using a random-effects method.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2010-03-02 01:36:43 -0500" MODIFIED_BY="[Empty name]">
<P>Ten trials in total met the inclusion criteria. Nine trials compared cisapride with placebo or no treatment, of which eight (262 participants) reported data on symptoms of gastro-oesophageal reflux. There was no statistically significant difference between the two interventions (OR 0.34; 95% CI 0.10 to 1.19) for 'same or worse' versus 'improved symptoms' at the end of treatment. There was significant heterogeneity between the studies, suggesting publication bias. Four studies reported adverse events (mainly diarrhoea); this difference was not statistically significant (OR 1.80; 95% CI 0.87 to 3.70). Another trial found no difference in the electrocardiographic QTc interval after three to eight weeks of treatment. Cisapride significantly reduced the reflux index (weighted mean difference -6.49; 95% CI -10.13 to -2.85; P = 0.0005). Other measures of oesophageal pH monitoring did not reach significance. One included study compared cisapride with Gaviscon (with no statistically significant difference). One small study found no evidence of benefit on frequency of regurgitation or weight gain after treatment with cisapride versus no treatment, carob bean or corn syrup thickeners.<BR/>
</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2010-02-28 17:23:25 -0500" MODIFIED_BY="[Empty name]">
<P>We found no clear evidence that cisapride reduces symptoms of GOR. Due to reports of fatal cardiac arrhythmias or sudden death, from July 2000 in the USA and Europe cisapride was restricted to a limited access programme supervised by a paediatric gastrologist.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2010-03-02 06:51:55 -0500" MODIFIED_BY="Cathy Bennett">
<BACKGROUND MODIFIED="2010-03-02 01:24:57 -0500" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2010-02-28 17:32:41 -0500" MODIFIED_BY="[Empty name]">
<P>Gastro-oesophageal reflux (GOR), or the passage of gastric contents into the oesophagus, has a multifactorial pathophysiology. Regurgitation of stomach contents into the oesophagus is normally prevented by the action of the lower oesophageal sphincter (LOS). Two different mechanisms contribute to LOS tone. These are the skeletal muscle of the diaphragm which surrounds the oesophagus as it passes through the diaphragm and the smooth muscle at the gastro-oesophageal junction. Low basal oesophageal sphincter pressure and transient relaxation of the LOS, oesophageal dysmotility resulting in impaired clearance, and delayed emptying of the stomach and duodenum can all contribute to GOR.</P>
<P>In most infants with GOR the outcome is benign. The determining factor in seeking medical assistance may be parental anxiety or intolerance of symptoms rather than the presence of significant complications. In a small minority, GOR is associated with significant problems such as respiratory sequelae (chronic cough, wheezing, apnoea, hoarseness, stridor, recurrent bronchitis, pneumonia), neuro-behavioural manifestations (back-arching, feeding refusal, rumination, non-specific irritability, sleep disturbance), oesophagitis, oesophageal strictures, and failure to thrive. The term gastro-oesophageal reflux disease (GORD) describes the association of definite pathology, in most cases oesophagitis, with reflux.</P>
<P>Infantile gastro-oesophageal reflux has a peak incidence around four months and resolves spontaneously by one to two years of age in most patients (<LINK REF="REF-Nelson-1997" TYPE="REFERENCE">Nelson 1997</LINK>; <LINK REF="REF-Rudolph-1996" TYPE="REFERENCE">Rudolph 1996</LINK>). A much smaller number of children have symptoms of GOR later in childhood; only some of these children will have had GOR in infancy. Less than 50% of children who develop reflux after the age of three years have spontaneous resolution of symptoms (<LINK REF="REF-Treem-1991" TYPE="REFERENCE">Treem 1991</LINK>). A substantial proportion of these children will have other problems including neurological or chronic respiratory disease.</P>
<P>A diagnosis of GOR is usually made on clinical grounds. Treatment for GOR, when this is deemed necessary, can be started before performing expensive and often unnecessary investigations (the Working Group of the European Society of Paediatric Gastro-Enterology and Nutrition (ESPGAN) on Gastro-Oesophageal Reflux, in <LINK REF="REF-Vandenplas-1993" TYPE="REFERENCE">Vandenplas 1993</LINK>). Though not always essential for diagnosis, there are a number of investigations available to assess the cause and quantity of the reflux and to detect the presence of reflux-related complications. Investigations are extended (18 to 24 hour) oesophageal pH monitoring, upper gastro-intestinal endoscopy, oesophageal manometry, scintigraphy or sonography. These have low sensitivities and specificities and do not allow correlation of the reflux episodes with the patient's symptoms. Moreover, these investigations are generally poor predictors of how children will respond to treatment (<LINK REF="REF-Cucchiara-1996" TYPE="REFERENCE">Cucchiara 1996</LINK>). A few variables, for example sleep reflux, acid clearing time, percentage time pH &lt; 4 and oesophageal motility parameters, may predict which children are likely to have continuing problems despite medical treatment (<LINK REF="REF-Colson-1990" TYPE="REFERENCE">Colson 1990</LINK>; <LINK REF="REF-Cucchiara-1996" TYPE="REFERENCE">Cucchiara 1996</LINK>; <LINK REF="REF-Varty-1993" TYPE="REFERENCE">Varty 1993</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2010-03-02 01:19:28 -0500" MODIFIED_BY="[Empty name]">
<P>There are four main types of therapy in infants with GOR: surgery, drugs, dietary measures (thickened feeds, frequent small meals) and positioning (avoidance of slumped seated or supine postures). Surgical treatment is usually reserved for complicated cases, while most cases are treated with some combination of the other options. Pharmacological therapies include acid-secretion inhibitors (for example cimetidine, ranitidine, omeprazole, lansoprazole) with or without prokinetic agents (for example cisapride, bethanechol, metoclopramide) when oesophagitis is present.</P>
</INTERVENTION>
<THEORY MODIFIED="2010-03-02 01:21:05 -0500" MODIFIED_BY="[Empty name]">
<P>Cisapride is administered orally 15 to 30 minutes before a meal to ensure maximum plasma levels of the medication immediately after food intake. It is a gastrointestinal prokinetic agent which stimulates lower oesophageal, gastric, small intestinal and colonic motility, probably acting by enhancing the release of acetylcholine at the level of the myenteric plexus in the gut wall.</P>
</THEORY>
<IMPORTANCE MODIFIED="2010-03-02 01:24:57 -0500" MODIFIED_BY="[Empty name]">
<P>Although cisapride has never been licensed for children under 12 years of age, it has been prescribed to over 36 million children worldwide (<LINK REF="REF-Vandenplas-1999" TYPE="REFERENCE">Vandenplas 1999</LINK>) including 19% of preterm newborns in Canadian neonatal units (<LINK REF="REF-Ward-1999" TYPE="REFERENCE">Ward 1999</LINK>). In 1999, a consensus statement by the European Society of Paediatric Gastroenterology, Hepatology and Nutrition (<LINK REF="REF-Vandenplas-1999" TYPE="REFERENCE">Vandenplas 1999</LINK>) recommended cisapride as the drug of first choice. stating that "the potential benefits far outweigh the potential risks and provide strong justification for its continued use". Since 1993 there have been 175 reports worldwide of fatal cardiac arrhythmia or sudden death associated with cisapride use, including at least two deaths in children, and 261 reports of non-fatal but serious ventricular arrhythmias (<LINK REF="REF-Klausner-1998" TYPE="REFERENCE">Klausner 1998</LINK>). These adverse events led to the withdrawal of cisapride from the UK and USA markets in July 2000 (<LINK REF="REF-Breckenridge-2000" TYPE="REFERENCE">Breckenridge 2000</LINK>; <LINK REF="REF-Henney-2000" TYPE="REFERENCE">Henney 2000</LINK>). To date, the effectiveness of cisapride for the treatment of reflux in children has not been systematically evaluated. As cisapride continues to be used, albeit within restricted programmes in the USA (<LINK REF="REF-Henney-2000" TYPE="REFERENCE">Henney 2000</LINK>) and Europe (<LINK REF="REF-EMEA-2002" TYPE="REFERENCE">EMEA 2002</LINK>), information on its effectiveness is required to enable clinicians and policy makers to decide whether the low risk of serious adverse events is outweighed by the benefits of treatment.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2010-03-02 01:25:49 -0500" MODIFIED_BY="[Empty name]">
<P>The objective of this review was to compare the effectiveness of cisapride in reducing the symptoms of gastro-oesophageal reflux with:<BR/>
<BR/>1. placebo or no treatment;<BR/>2. other medical treatments;<BR/>3. dietary interventions;<BR/>4. positioning;<BR/>5. any combination of the other treatments.</P>
</OBJECTIVES>
<METHODS MODIFIED="2010-03-02 06:51:55 -0500" MODIFIED_BY="Cathy Bennett">
<SELECTION_CRITERIA MODIFIED="2010-03-02 01:45:17 -0500" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2010-03-02 01:28:06 -0500" MODIFIED_BY="[Empty name]">
<P>Searches were carried out for randomised controlled trials comparing oral cisapride therapy with placebo or other non-surgical treatments (other prokinetic drugs, with or without acid-secretion inhibitors, dietary measures, positioning) in children with gastro-oesophageal reflux. Searches for unpublished data are ongoing.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2010-03-02 01:31:32 -0500" MODIFIED_BY="[Empty name]">
<P>Children (aged less than 18 years) with a diagnosis of gastro-oesophageal reflux, however defined. We excluded trials in which the majority of participants were aged less than 28 days. This is because cisapride is prescribed to neonates for feed intolerance, which is a different clinical entity from gastro-oesophageal reflux that may be due to different physiological mechanisms. It may respond differently to cisapride than does GORD in older children (<LINK REF="STD-Enriquez-1998" TYPE="STUDY">Enriquez 1998</LINK>).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2010-03-02 01:32:15 -0500" MODIFIED_BY="[Empty name]">
<OL>
<LI>Cisapride versus no treatment or placebo</LI>
<LI>Cisapride versus other medical therapies (bethanechol, metoclopramide, cimetidine, ranitidine, omeprazole, lansoprazole, Gaviscon)</LI>
<LI>Cisapride versus dietary interventions (small meals, thickened infant feeds)</LI>
<LI>Cisapride versus positioning (avoidance of slumped seated or supine postures)</LI>
<LI>Cisapride versus any combination of other non-surgical therapies</LI>
</OL>
<P>Because of the restriction of surgical treatment to complicated cases of GOR, we did not expect to find randomised controlled trials in this area and they were not sought.</P>
<P>We looked for studies in which cisapride was administered orally for a minimum of one week.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2010-03-02 01:45:17 -0500" MODIFIED_BY="[Empty name]">
<P>Cisapride treatment usually precedes physiological investigations for GOR and primarily aims to improve symptoms and avoid serious complications of GOR.</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2010-03-02 01:35:29 -0500" MODIFIED_BY="[Empty name]">
<UL>
<LI>Symptoms, or changes in symptoms, of gastro-oesophageal reflux (regurgitation, crying, irritability, vomiting, gagging) assessed subjectively by the parent or guardian of the child or by the treating physician, or both.</LI>
<LI>Presence of any of the following adverse events: abdominal pain, borborygmi, diarrhoea, headaches, hypersensitivity, convulsions, extrapyramidal effects, increased urinary frequency, liver function abnormalities, increased QTc interval on the electrocardiogram (ECG).</LI>
<LI>Occurrence of any clinical complications of GOR, e.g. respiratory symptoms.</LI>
<LI>Weight gain.</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2010-03-02 01:45:17 -0500" MODIFIED_BY="[Empty name]">
<UL>
<LI>Episodes of reflux measured by extended duration oesophageal pH monitoring: percentage of time during which pH &lt; 4 ('reflux index'), number of episodes of pH &lt; 4, number of episodes of pH &lt; 4 lasting &gt; 5 minutes, duration of longest episode of pH &lt; 4.</LI>
<LI>Lower oesophageal sphincter (LOS) pressure measured by oesophageal manometry.</LI>
<LI>Histological evidence of oesophagitis on biopsy.</LI>
</UL>
<P>Included studies had to report at least one of the primary outcomes.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2010-03-02 01:51:07 -0500" MODIFIED_BY="[Empty name]">
<P>See: Cochrane Upper Gastrointestinal and Pancreatic Diseases Review Group search strategy</P>
<P>For the first version of this review, searches were conducted of the Cochrane Central Trials Register (CCTR) and the specialised trials register of the Cochrane Upper Gastrointestinal and Pancreatic Diseases Group (see Review Group details for more information) using terms related to gastro-oesophageal reflux and cisapride. In addition, the review authors searched the MEDLINE and EMBASE electronic databases. The search strategy included appropriate MeSH terms and text terms including: cisapride, gastro-oesophageal reflux, idiopathic gastro-oesophageal reflux, uncomplicated gastro-oesophageal reflux, gastro-oesophageal reflux disease, infantile reflux, regurgitation, excessive regurgitation, and with appropriate truncations and misspellings. These were combined with the use of the most sensitive Cochrane trials filters. Reference lists of relevant review articles and identified trials were scrutinised and forward citation searches were performed in the Science Citation Index on all trials identified. The drug manufacturers were contacted for any unpublished trials.</P>
<P>Searches were updated on <I>The Cochrane Library, </I>pre-MEDLINE, EMBASE (5 April 2002) using the above strategy. An adapted strategy was used for PubMed. The pharmaceutical company Janssen was contacted for unpublished trials. The searches were re-run in August 2003, May 2004, June 2005 and June 2006 and no new trials were found.</P>
<P>For the update in 2009, trials were identified by searching the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> 2008, Issue 4), MEDLINE (2005 to February 2009) and EMBASE (2005 to February 2009). We did not confine our search to English language publications.<BR/>
<BR/>The Cochrane highly sensitive search strategy for identifying randomised trials in MEDLINE, sensitivity maximising version, Ovid format (<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>) was combined with the search terms in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> in order to identify randomised controlled trials in MEDLINE. The MEDLINE search strategy was adapted for use in the other databases that were searched.<BR/>
</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2010-03-02 06:51:55 -0500" MODIFIED_BY="Cathy Bennett">
<P>
<BR/>
</P>
<STUDY_SELECTION MODIFIED="2010-03-02 01:51:47 -0500" MODIFIED_BY="[Empty name]">
<P>Titles and abstracts of all studies identified by the electronic searches were independently reviewed on screen by two review authors (CA, SM).</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2010-03-02 01:53:05 -0500" MODIFIED_BY="[Empty name]">
<P>All potentially eligible studies were retrieved in hard copy and were independently reviewed by two researchers (CA, SM in 2002; SM, RG in 2009) against the inclusion criteria. Disagreements were resolved by consensus with provision for arbitration by a third review author, if required (RG or SL). Additional information was sought for one included trial (<LINK REF="STD-Cohen-1999" TYPE="STUDY">Cohen 1999</LINK>). The reasons for exclusion of trials are given in the table '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>'.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2010-03-02 01:54:34 -0500" MODIFIED_BY="[Empty name]">
<P>The methodological quality of the included trials was assessed independently by two review authors (CA, SM in 2002; SM, RG in 2009) using a checklist developed for this purpose. For each included trial, information was collected regarding the method of randomisation, allocation concealment, blinding of outcome assessment, and the relevant interventions and outcomes. Data were extracted independently by two review authors (CA, SM in 2002; RG and LCG in 2009) and any discrepancies were discussed and resolved. Data were then entered into the Review Manager software by one review author (CA or LCG) and accuracy was checked by two other authors (SM, RG).</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2010-03-02 06:14:01 -0500" MODIFIED_BY="Cathy Bennett">
<P>For dichotomous data, a random effects model meta-analysis was performed to determine a summary odds ratio (OR). Where continuous data outcomes were measured in a standard way across studies (for example reflux index), the pooled weighted mean difference (WMD) was calculated again using a random effects model. The denominators for these calculations were all children for whom outcome data had been reported. Analysis was by intention to treat. Sensitivity analyses involved re-calculation of the summary OR for trials with good allocation concealment. For the primary outcome of 'same or worse' symptoms we analysed funnel plot asymmetry, and hence the likelihood of bias, using the regression method as described by Egger et al (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>). Evidence of heterogeneity was sought using a standard Chi<SUP>2</SUP> statistic.</P>
</EFFECT_MEASURES>
<HETEROGENEITY_ASSESSMENT MODIFIED="2010-03-02 06:51:55 -0500" MODIFIED_BY="Cathy Bennett">
<P>To assess heterogeneity, we conducted subgroup analyses according to study quality and produced a funnel plot for the primary outcome 'same or worse symptoms versus improvement' (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
</HETEROGENEITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2010-03-02 02:14:54 -0500" MODIFIED_BY="[Empty name]">
<P>We preferentially included symptoms assessed by parents as the parents are likely to have greater contact with their child and therefore have a more accurate view of the change in symptoms. However, we included physician measures of symptoms where parental assessments were not available, as we considered that they were assessing the same entity.</P>
<P>Studies reported symptoms or changes in symptoms at the end of the treatment period in a variety of ways. An a priori decision was made to dichotomise data as 'same or worse' versus 'improvement'. In a sensitivity analysis we examined the effect of redefining the outcomes as 'any symptoms' versus 'no symptoms'. Decisions about how best to dichotomise the data were reached by two review authors (RG, SL) without knowledge of the results. Changes in oesophageal pH measurements at the end of treatment were considered to be a secondary outcome as pH measurements are not reliable (<LINK REF="REF-Hampton-1990" TYPE="REFERENCE">Hampton 1990</LINK>); they correlate poorly with symptoms and the response to treatment (<LINK REF="REF-Cucchiara-1996" TYPE="REFERENCE">Cucchiara 1996</LINK>). We were able to analyse results for the reflux index (percentage of 24 hrs with oesophageal pH &lt; 4) as this was the most commonly reported measure.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2010-03-02 02:17:37 -0500" MODIFIED_BY="[Empty name]">
<P>Planned subgroup analyses were: in children under and over the age of one year, uncomplicated and complicated gastro-oesophageal reflux, for those with neurological impairment, and in trials where the assessment of outcomes was blinded versus those in which assessment was non-blinded. These were not conducted as appropriate trials were not identified.</P>
</SUBGROUP_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2010-03-02 06:45:30 -0500" MODIFIED_BY="Cathy Bennett">
<STUDY_DESCRIPTION MODIFIED="2010-03-02 06:17:54 -0500" MODIFIED_BY="Cathy Bennett">
<SEARCH_RESULTS MODIFIED="2010-03-02 02:19:22 -0500" MODIFIED_BY="[Empty name]">
<P>Ten trials met the inclusion criteria (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>). Nine of these compared the effects of cisapride with placebo or no treatment (<LINK REF="STD-Cohen-1999" TYPE="STUDY">Cohen 1999</LINK>; <LINK REF="STD-Cucchiara-1987" TYPE="STUDY">Cucchiara 1987</LINK>; <LINK REF="STD-Escobar-Castro-1994" TYPE="STUDY">Escobar Castro 1994</LINK>; <LINK REF="STD-Levy-2001" TYPE="STUDY">Levy 2001</LINK>; <LINK REF="STD-Moya-1999" TYPE="STUDY">Moya 1999</LINK>; <LINK REF="STD-Scott-1997" TYPE="STUDY">Scott 1997</LINK>; <LINK REF="STD-Van-Eygen-1989_x0028_a_x0029_" TYPE="STUDY">Van Eygen 1989(a)</LINK>; <LINK REF="STD-Van-Eygen-1989_x0028_b_x0029_" TYPE="STUDY">Van Eygen 1989(b)</LINK>; <LINK REF="STD-Vandenplas-1991" TYPE="STUDY">Vandenplas 1991</LINK>). Limited results were reported from an unpublished study of symptomatic children over two months old with biopsy-proven oesophagitis that compared cisapride with cimetidine and placebo (<LINK REF="STD-Orenstein-2000" TYPE="STUDY">Orenstein 2000</LINK>). The results were published only in abstract form but the lead investigator provided a summary in a personal communication. Due to the limited nature of the data provided (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>), this study could not be included in our analysis.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2010-03-02 06:17:54 -0500" MODIFIED_BY="Cathy Bennett">
<P>In two studies (<LINK REF="STD-Scott-1997" TYPE="STUDY">Scott 1997</LINK>; <LINK REF="STD-Vandenplas-1991" TYPE="STUDY">Vandenplas 1991</LINK>) positioning or thickened feeds, or both, were given in both the experimental and control arms. One paper (<LINK REF="STD-Van-Eygen-1989_x0028_a_x0029_" TYPE="STUDY">Van Eygen 1989(a)</LINK>,(b)) presented data from three trials. Two of these were on different patient populations and met our inclusion criteria; they were reviewed separately and are identified accordingly. In one trial (<LINK REF="STD-Greally-1992" TYPE="STUDY">Greally 1992</LINK>) cisapride was compared with Gaviscon with or without Carobel. The most recently identified study was a four-arm trial with six to eight participants in each arm. This study compared cisapride with no treatment and with thickened feeds using carob bean or corn syrup (<LINK REF="STD-Moya-1999" TYPE="STUDY">Moya 1999</LINK>). The study reported on two of our primary outcomes: change in the number of regurgitations and weight gain.</P>
<P>Most studies reported outcomes based on a change in symptoms following the intervention. The exceptions were: the <LINK REF="STD-Escobar-Castro-1994" TYPE="STUDY">Escobar Castro 1994</LINK> study which reported symptoms at the end of the treatment period; and the study by <LINK REF="STD-Cucchiara-1987" TYPE="STUDY">Cucchiara 1987</LINK> in which improvement in symptoms alone could not be separated from improvement in the pH probe results and histopathological changes. Both these studies were included and their contribution to the overall results was explored in a sensitivity analysis. <LINK REF="STD-Moya-1999" TYPE="STUDY">Moya 1999</LINK> did not report overall symptom improvement for each participant but analysed mean number of regurgitations during the treatment period as well as mean daily weight gain.</P>
<P>The study by <LINK REF="STD-Levy-2001" TYPE="STUDY">Levy 2001</LINK> only reported data on the QTc interval of the ECG. These data were from a seven-centre double-blind, placebo-controlled study of 134 children on the safety and efficacy of cisapride. It was conducted from 1991 to 1994 with the support of Janssen Pharmaceutical Inc. Levy et al stated that "because efficacy results did not reach statistical significance (possibly because inclusion criteria were too broadly defined), they were not published". The response to a request to Janssen-Cilag Ltd UK for unpublished data was that they were not aware of any unpublished data. No further information has been provided.<BR/>
<BR/>The children included in the trials were aged between five days and five years. They had a diagnosis of GOR, defined by clinical symptoms alone or with additional oesophageal pH monitoring. Children were generally excluded from the trials if they: required concomitant therapy with drugs interfering with assessment of the study drug; had reflux caused by known anatomic abnormalities; had underlying disease; had an infection of the gastrointestinal (GI) tract or other organ system; or had neurologic, metabolic, or renal disorders (see table '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>').</P>
<P>The dosage of cisapride that was used was 0.8 mg/kg/day, with three exceptions: in one study (<LINK REF="STD-Cucchiara-1987" TYPE="STUDY">Cucchiara 1987</LINK>) 0.9 mg/kg/day was used, in another (<LINK REF="STD-Van-Eygen-1989_x0028_a_x0029_" TYPE="STUDY">Van Eygen 1989(a)</LINK>) 0.45 mg/kg/day, and in another study (<LINK REF="STD-Levy-2001" TYPE="STUDY">Levy 2001</LINK>) 0.6 mg/kg/day. One study (<LINK REF="STD-Moya-1999" TYPE="STUDY">Moya 1999</LINK>) stated that the usual dosage was given in three divided doses but did not specify the amount. The duration of follow up varied slightly over all studies: four studies followed participants up for two weeks (<LINK REF="STD-Cohen-1999" TYPE="STUDY">Cohen 1999</LINK>; <LINK REF="STD-Cucchiara-1987" TYPE="STUDY">Cucchiara 1987</LINK>; <LINK REF="STD-Moya-1999" TYPE="STUDY">Moya 1999</LINK>; <LINK REF="STD-Vandenplas-1991" TYPE="STUDY">Vandenplas 1991</LINK>); four studies up to four weeks (<LINK REF="STD-Escobar-Castro-1994" TYPE="STUDY">Escobar Castro 1994</LINK>; <LINK REF="STD-Greally-1992" TYPE="STUDY">Greally 1992</LINK>; <LINK REF="STD-Van-Eygen-1989_x0028_a_x0029_" TYPE="STUDY">Van Eygen 1989(a)</LINK>; <LINK REF="STD-Van-Eygen-1989_x0028_b_x0029_" TYPE="STUDY">Van Eygen 1989(b)</LINK>); one up to six weeks (<LINK REF="STD-Scott-1997" TYPE="STUDY">Scott 1997</LINK>), and another for eight weeks (<LINK REF="STD-Greally-1992" TYPE="STUDY">Greally 1992</LINK>). In five of the nine included trials that compared the effects of cisapride with placebo or no treatment cisapride had been supplied by the manufacturing company (<LINK REF="STD-Cohen-1999" TYPE="STUDY">Cohen 1999</LINK>; <LINK REF="STD-Greally-1992" TYPE="STUDY">Greally 1992</LINK>; <LINK REF="STD-Scott-1997" TYPE="STUDY">Scott 1997</LINK>; <LINK REF="STD-Van-Eygen-1989_x0028_a_x0029_" TYPE="STUDY">Van Eygen 1989(a)</LINK>; <LINK REF="STD-Van-Eygen-1989_x0028_b_x0029_" TYPE="STUDY">Van Eygen 1989(b)</LINK>).</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2010-03-02 02:41:01 -0500" MODIFIED_BY="[Empty name]">
<P>Eight studies identified by the search strategy were excluded: in two (<LINK REF="STD-Cucchiara-1990" TYPE="STUDY">Cucchiara 1990</LINK>; <LINK REF="STD-Saye-1987" TYPE="STUDY">Saye 1987</LINK>) cisapride had been given for less than 24 hours; in three (<LINK REF="STD-Barnett-2001" TYPE="STUDY">Barnett 2001</LINK>; <LINK REF="STD-Pezzati-2001" TYPE="STUDY">Pezzati 2001</LINK>; <LINK REF="STD-McClure-1999" TYPE="STUDY">McClure 1999</LINK>) cisapride was administered to preterm infants with feed intolerance; in two studies cisapride was administered prophylactically to preterm infants for feed intolerance (<LINK REF="STD-Enriquez-1998" TYPE="STUDY">Enriquez 1998</LINK>; <LINK REF="STD-Reddy-2000" TYPE="STUDY">Reddy 2000</LINK>); and two studies did not report any of the outcomes required for inclusion in the review (<LINK REF="STD-Heine-1996" TYPE="STUDY">Heine 1996</LINK>; <LINK REF="STD-McClure-1999" TYPE="STUDY">McClure 1999</LINK>). Please see the '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>' table for further details.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2010-03-02 06:34:32 -0500" MODIFIED_BY="Cathy Bennett">
<P>Two trials reported adequate allocation concealment (<LINK REF="STD-Cohen-1999" TYPE="STUDY">Cohen 1999</LINK>; <LINK REF="STD-Scott-1997" TYPE="STUDY">Scott 1997</LINK>). In the remaining eight trials the method used for allocation concealment was unclear (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). In one study (<LINK REF="STD-Greally-1992" TYPE="STUDY">Greally 1992</LINK>) a double-blind design was not feasible due to the different mode of preparation and time of administration of cisapride and Gaviscon with or without Carobel. Eight trials stated that they were double blind (<LINK REF="STD-Cohen-1999" TYPE="STUDY">Cohen 1999</LINK>; <LINK REF="STD-Cucchiara-1987" TYPE="STUDY">Cucchiara 1987</LINK>; <LINK REF="STD-Escobar-Castro-1994" TYPE="STUDY">Escobar Castro 1994</LINK>; <LINK REF="STD-Greally-1992" TYPE="STUDY">Greally 1992</LINK>; <LINK REF="STD-Levy-2001" TYPE="STUDY">Levy 2001</LINK>; <LINK REF="STD-Scott-1997" TYPE="STUDY">Scott 1997</LINK>; <LINK REF="STD-Van-Eygen-1989_x0028_a_x0029_" TYPE="STUDY">Van Eygen 1989(a)</LINK>; <LINK REF="STD-Vandenplas-1991" TYPE="STUDY">Vandenplas 1991</LINK>; <LINK REF="STD-Van-Eygen-1989_x0028_b_x0029_" TYPE="STUDY">Van Eygen 1989(b)</LINK>). Details of blinding of participants were often given but no trial gave explicit information on the blinding of key study personnel for the duration of the study (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). The most recent study to be included in this review (<LINK REF="STD-Moya-1999" TYPE="STUDY">Moya 1999</LINK>) was not blinded and provided no information on how randomisation was performed or how allocation was concealed.</P>
<P>In one study all of the randomised infants completed the study (<LINK REF="STD-Greally-1992" TYPE="STUDY">Greally 1992</LINK>). Losses to follow up in the other studies varied from as little as one and three (<LINK REF="STD-Cucchiara-1987" TYPE="STUDY">Cucchiara 1987</LINK>; <LINK REF="STD-Escobar-Castro-1994" TYPE="STUDY">Escobar Castro 1994</LINK>), respectively, to as much as 30% of the randomised population in three studies (<LINK REF="STD-Cohen-1999" TYPE="STUDY">Cohen 1999</LINK>; <LINK REF="STD-Levy-2001" TYPE="STUDY">Levy 2001</LINK>; <LINK REF="STD-Vandenplas-1991" TYPE="STUDY">Vandenplas 1991</LINK>). In the study by <LINK REF="STD-Cucchiara-1987" TYPE="STUDY">Cucchiara 1987</LINK> the total number of participants included was reported, as was the number of participants for each group who completed the trial; the number randomised to the treatment and control arms was not. For this study we made the assumption that randomisation had produced equal numbers in each group. <LINK REF="STD-Moya-1999" TYPE="STUDY">Moya 1999</LINK> provided no information on losses to follow up but we assumed that all participants completed the study.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2010-03-02 06:45:30 -0500" MODIFIED_BY="Cathy Bennett">
<SUBSECTION>
<HEADING LEVEL="3">Cisapride versus placebo or no treatment</HEADING>
<P>Eight trials including 262 participants compared symptoms of GOR after treatment with cisapride or no treatment. Analysis of symptoms was based on parental evaluation in five trials (<LINK REF="STD-Cohen-1999" TYPE="STUDY">Cohen 1999</LINK>; <LINK REF="STD-Escobar-Castro-1994" TYPE="STUDY">Escobar Castro 1994</LINK>; <LINK REF="STD-Moya-1999" TYPE="STUDY">Moya 1999</LINK>; <LINK REF="STD-Scott-1997" TYPE="STUDY">Scott 1997</LINK>; <LINK REF="STD-Vandenplas-1991" TYPE="STUDY">Vandenplas 1991</LINK>) and physician assessment in the remaining three trials (<LINK REF="STD-Cucchiara-1987" TYPE="STUDY">Cucchiara 1987</LINK>; <LINK REF="STD-Van-Eygen-1989_x0028_a_x0029_" TYPE="STUDY">Van Eygen 1989(a)</LINK>; <LINK REF="STD-Van-Eygen-1989_x0028_b_x0029_" TYPE="STUDY">Van Eygen 1989(b)</LINK>). The pooled OR (random-effects model) for cisapride versus placebo for 'same or worse' symptoms versus 'improvement' based on seven trials (excluding <LINK REF="STD-Moya-1999" TYPE="STUDY">Moya 1999</LINK>) was 0.34 (95% CI 0.10 to 1.19) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). The trial by <LINK REF="STD-Moya-1999" TYPE="STUDY">Moya 1999</LINK> showed no significant difference in the number of regurgitations per day between groups treated with cisapride or no treatment, at 15 days follow up (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
<P>The OR for cisapride versus placebo for 'same or worse' versus 'improvement' in symptoms after exclusion of the study by <LINK REF="STD-Escobar-Castro-1994" TYPE="STUDY">Escobar Castro 1994</LINK> (OR 0.59; 95% CI 0.22 to 1.59) or <LINK REF="STD-Cucchiara-1987" TYPE="STUDY">Cucchiara 1987</LINK> (OR 0.41; 95% CI 0.11 to 1.54) did not change appreciably (data not shown). Analysis of the effects of cisapride after re-defining outcomes as 'any symptoms' versus 'no symptoms' was restricted to five trials (a total of 156 participants) (<LINK REF="STD-Cucchiara-1987" TYPE="STUDY">Cucchiara 1987</LINK>; <LINK REF="STD-Escobar-Castro-1994" TYPE="STUDY">Escobar Castro 1994</LINK>; <LINK REF="STD-Scott-1997" TYPE="STUDY">Scott 1997</LINK>; <LINK REF="STD-Van-Eygen-1989_x0028_a_x0029_" TYPE="STUDY">Van Eygen 1989(a)</LINK>; <LINK REF="STD-Van-Eygen-1989_x0028_b_x0029_" TYPE="STUDY">Van Eygen 1989(b)</LINK>; <LINK REF="STD-Vandenplas-1991" TYPE="STUDY">Vandenplas 1991</LINK>). The pooled OR (random-effects model) for cisapride versus no treatment was 0.19 (95% CI 0.08 to 0.44) (<LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>).</P>
<P>The analysis of 'same or worse' versus 'improvement' in symptoms showed significant heterogeneity (Chi<SUP>2</SUP> = 24.23; df = 6; P = 0.0005; I<SUP>2 </SUP>= 75%) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). The reasons for the heterogeneity were not obvious from examination of the included trials, which were conducted in clinically similar populations and reported similar baseline event rates. The funnel plot was asymmetrical, suggesting an absence of small studies showing small or no benefit of cisapride. The intercept was -5.07 (95% CI -7.18 to -2.95). This result is consistent with publication bias favouring studies that showed a positive effect of cisapride. The results regarding the benefits of cisapride should therefore be interpreted with caution.</P>
<SUBSECTION>
<HEADING LEVEL="4">Adverse events</HEADING>
<P>Adverse events (principally diarrhoea) were reported in four trials (a total of 190 participants). There were fewer adverse events in the non-treatment group than in the cisapride group but the difference was not statistically significant (OR for cisapride versus placebo 1.86; 95% CI 0.88 to 3.93) (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>). One trial (<LINK REF="STD-Levy-2001" TYPE="STUDY">Levy 2001</LINK>) reported data on the QTc interval following three to eight weeks of either cisapride or placebo. No statistically significant differences were found between the two groups in either total QTc interval duration or change in QTc interval compared to baseline. Mean QTc was 408 ± 21 ms in the cisapride group and 399 ± 21 ms in the placebo group; the change in QTc was 1.7 ± 18 ms and 2.4 ± 20 ms, respectively.</P>
<P>A primary outcome for our study was weight gain following the intervention but only two studies reported this outcome (<LINK REF="STD-Cohen-1999" TYPE="STUDY">Cohen 1999</LINK>; <LINK REF="STD-Moya-1999" TYPE="STUDY">Moya 1999</LINK>). For the study by <LINK REF="STD-Cohen-1999" TYPE="STUDY">Cohen 1999</LINK> the mean difference in weight gain at the end of the two week trial was based on data provided by the authors. In the study by <LINK REF="STD-Cohen-1999" TYPE="STUDY">Cohen 1999</LINK> the difference between the two groups was not statistically significant (0.9 kg; 95% CI -0.38 to 2.18) (data not shown). <LINK REF="STD-Moya-1999" TYPE="STUDY">Moya 1999</LINK> reported no difference in mean daily weight gain between infants given cisapride and those with no treatment (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
<P>Use of cisapride was associated with a reduction in the reflux index, as measured by oesophageal pH monitoring, in five studies. The weighted mean difference for cisapride versus no treatment was -6.49 (95% CI -10.13 to -2.85) (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). Several other physiological measured were reported. The differences between the cisapride and the placebo groups were not statistically significant for: number of episodes of pH &lt; 4 in 24 hours (data available from two studies), number of reflux episodes lasting more than 5 min (data from three studies), or number over the course of a day (one study).</P>
<P>For this review we also looked for histological evidence of oesophagitis at biopsy. Three trials reported data. In <LINK REF="STD-Cohen-1999" TYPE="STUDY">Cohen 1999</LINK> only six of 68 participants underwent endoscopy and there was no difference in the presence of 'mild histologic oesophagitis' between the cisapride and the placebo group (2/4 versus 1/2). In <LINK REF="STD-Cucchiara-1987" TYPE="STUDY">Cucchiara 1987</LINK> the degree of oesophagitis was histologically defined as 'mild', 'moderate' or 'severe' and transformed into a score. Cisapride was more effective than placebo but only three of the 17 participants included in the study had severe oesophagitis at the beginning. In <LINK REF="STD-Scott-1997" TYPE="STUDY">Scott 1997</LINK> the biopsy was repeated at the end of the trial only if oesophagitis had been present at baseline. The difference in abnormal findings between the cisapride and the placebo groups (7/11 versus 5/9) was not statistically significant.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Cisapride versus other medical interventions (Gaviscon)</HEADING>
<P>One study comparing cisapride with Gaviscon (or Gaviscon and carob bean thickener in 21 of the 24 cases) was identified (<LINK REF="STD-Greally-1992" TYPE="STUDY">Greally 1992</LINK>). The 'same or worse symptoms' were slightly more common in the cisapride group than in the Gaviscon group but this difference was not significant (OR 3.26; 95% CI 0.93 to 11.38) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>). The outcomes in this study were based on evaluations by parents who were not blind to the intervention.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Cisapride versus <I>dietary</I> interventions</HEADING>
<P>One study compared cisapride with two dietary interventions, carob bean thickener and corn syrup (<LINK REF="STD-Moya-1999" TYPE="STUDY">Moya 1999</LINK>). As the authors did not provide details of overall symptom improvement for each patient, we were not able to calculate an OR for 'same or worse' versus 'improvement' in symptoms (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>). There was no significant difference in the number of regurgitations per day at the end of 15 days follow up between infants treated with cisapride, carob bean or corn syrup (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>; <LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>). There was a greater mean daily weight gain in infants given corn syrup compared with cisapride (MD -3.70; 95% CI -10.46 to 3.06) (<LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK>) but no significant difference between carob bean and cisapride (<LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>). No adverse events were reported when comparing cisapride against the other interventions.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2010-03-02 06:51:55 -0500" MODIFIED_BY="Cathy Bennett">
<SUMMARY_OF_RESULTS MODIFIED="2010-03-02 03:11:09 -0500" MODIFIED_BY="[Empty name]">
<P>We found no clear evidence for a significant effect of cisapride compared with placebo on symptoms of GOR in children. However, the midpoint estimate of the<B> </B>summary OR was 0.34<B>.</B> This result is likely to be an overestimate of the benefits of cisapride.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2010-03-02 06:51:55 -0500" MODIFIED_BY="Cathy Bennett">
<P>The analysis of funnel plot asymmetry showed that the intercept from the regression analysis was -5.07 (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). In an analysis of 75 meta-analyses published in <I>The Cochrane Library</I> and in four leading journals, <LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK> reported intercepts varying from -3.5 to +3.5. In comparison, our result shows extreme asymmetry reflecting an inverse association between study precision and an apparent beneficial effect of cisapride. While this relationship may reflect real differences between large and smaller trials, it may be explained by publication bias favouring submission or publication of small positive studies rather than small negative studies. This possibility is supported by the report of a multicentre trial of 96 children randomised to either cisapride or placebo (with or without cimetidine) which was not published "because efficacy results did not reach statistical significance (possibly because inclusion criteria were too broadly defined)" (<LINK REF="STD-Levy-2001" TYPE="STUDY">Levy 2001</LINK>). The six smallest studies in this review had unclear allocation concealment, which has been reported to be associated with an overestimate of treatment effect (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>). If the analysis was restricted to the two trials with good allocation concealment the summary OR was 1.94 (95%CI 0.87 to 4.31) (data not shown).</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2010-03-02 03:14:28 -0500" MODIFIED_BY="[Empty name]">
<P>There was substantial heterogeneity of results between trials. The source of this heterogeneity is unclear as there was no obvious clinical heterogeneity (age, method of GOR diagnosis, dose and duration of interventions were broadly similar).</P>
<P>We found a statistically significant reduction in the reflux index with cisapride compared to no treatment. The reflux index is generally taken to be the percentage of time with pH &lt; 4 over 24 hours of pH monitoring; the reduction suggested by this analysis was equivalent to 1.5 hours (with 95% CI of 40 minutes to almost 2.5 hours). This finding however has to be seen in the context of a lack of correlation between the reflux index and clinical symptoms and the evidence of publication bias.</P>
<P>A small study was found which compared the use of cisapride with Gaviscon or a combination of Gaviscon and carob bean thickener (<LINK REF="STD-Greally-1992" TYPE="STUDY">Greally 1992</LINK>), the results did not reach conventional levels of statistical significance. A further study showed no difference between cisapride and carob bean thickener or corn syrup for mean daily regurgitation frequency or daily weight gain (<LINK REF="STD-Moya-1999" TYPE="STUDY">Moya 1999</LINK>).</P>
<P>This review did not find a statistically significant difference in adverse events between cisapride and no treatment. However, serious adverse events are rare and are unlikely to be detected by small trials. Recent reports from surveillance studies of death and life threatening events potentially related to cisapride, together with the uncertain benefits of cisapride, have led to the decision to stop marketing cisapride in the United States (<LINK REF="REF-Henney-2000" TYPE="REFERENCE">Henney 2000</LINK>).</P>
</QUALITY_OF_EVIDENCE>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2010-03-02 03:17:36 -0500" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2010-03-02 03:16:53 -0500" MODIFIED_BY="[Empty name]">
<P>Our findings of a lack of evidence for a beneficial effect of cisapride contradict previous widely held opinions to the contrary (<LINK REF="REF-Shulman-2000" TYPE="REFERENCE">Shulman 2000</LINK>; <LINK REF="REF-Vandenplas-1999" TYPE="REFERENCE">Vandenplas 1999</LINK>). This review found no statistically significant effect of cisapride on symptoms of GOR, although the results were consistent with a substantial reduction, no effect, or even an increase in symptoms associated with cisapride treatment compared with placebo. In this review there was evidence of substantial funnel plot asymmetry which may be explained by publication bias. There was also statistical heterogeneity between the trials that may be related to variation in study quality. For these reasons, the results are uncertain and should be interpreted with caution. Finally, this review has highlighted the paucity of randomised controlled trial information for such a widely prescribed drug. However, due to the potential for serious adverse events, large randomised trials of cisapride that have long-term follow up are unlikely to be conducted.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2010-03-02 03:17:36 -0500" MODIFIED_BY="[Empty name]">
<P>The literature search did not find sufficient trials to fulfil all the objectives of this review. Due to the restricted use of cisapride since July 2000, a larger study to determine the effectiveness of cisapride for children with GOR is no longer possible.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2010-03-02 03:18:07 -0500" MODIFIED_BY="[Empty name]">
<P>We thank Professor Geoffrey P Davidson for providing additional information for one study trial; Dr Billy Bourke, Professor B Drumm and Dr Jaqui Dalby-Payne for their comments on the first draft of the original review; Susan Orenstein for her comments on a subsequent version and for a personal communication about the results of her unpublished study; and Melissa Harden for assisting in the search for unpublished trials from the pharmaceutical company Janssen.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2010-02-28 17:54:02 -0500" MODIFIED_BY="[Empty name]">
<P>None known</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2010-03-02 03:18:34 -0500" MODIFIED_BY="[Empty name]">
<P>All review authors contributed to the design of the study, the development of the protocol, the writing of the original version of this review. All authors, apart from CA, contributed to the 2009 update.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES MODIFIED="2010-03-02 03:19:09 -0500" MODIFIED_BY="[Empty name]">
<P>All authors contributed to the overall design of the review and the development of the protocol for study inclusion and data extraction.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2010-03-02 07:06:15 -0500" MODIFIED_BY="Cathy Bennett">
<STUDIES MODIFIED="2010-03-02 05:06:48 -0500" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2010-03-02 05:06:48 -0500" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="MIX" ID="STD-Cohen-1999" MODIFIED="2010-02-07 05:39:54 -0500" MODIFIED_BY="[Empty name]" NAME="Cohen 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-01-12 09:00:07 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cohen RC, O'Loughlin EV, Davidson GP, Moore DJ, Lawrence DM</AU>
<TI>Cisapride in the control of symptoms in infants with gastroesophageal reflux. A randomized, double-blind, placebo-controlled trial</TI>
<SO>Journal of Pediatrics</SO>
<YR>1999</YR>
<VL>134</VL>
<PG>287-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-02-07 05:39:54 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Note to Cathy - as per our email communication - additional information regarding trial characteristics obtained when SM met with GD - 14.9.99.  Additional data obtained about the same time (possibly on same date - not recorded at the time), so I have kept this as a single reference, and noted the type of communication as a &amp;quot;meeting&amp;quot;, as you suggested. thanks&lt;/p&gt;" NOTES_MODIFIED="2010-02-07 05:39:54 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CORRESPONDENCE">
<AU>Davidson GP</AU>
<TI>Personal communication</TI>
<TO>Clarification of trial characteristics and additional data</TO>
<SO>Meeting</SO>
<YR>14.09.99</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cucchiara-1987" MODIFIED="2010-01-12 09:00:45 -0500" MODIFIED_BY="[Empty name]" NAME="Cucchiara 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-01-12 09:00:45 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cucchiara S, Staiano A, Capozzi C, Di Lorenzo C, Boccieri A, Auricchio S</AU>
<TI>Cisapride for gastro-oesophageal reflux and peptic oesophagitis</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1987</YR>
<VL>62</VL>
<PG>454-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Escobar-Castro-1994" MODIFIED="2010-01-26 05:59:07 -0500" MODIFIED_BY="[Empty name]" NAME="Escobar Castro 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-01-26 05:59:07 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Escobar Castro H, Bettas Ferrero G, Suarez Cortina L, Camarero&lt;/p&gt;" NOTES_MODIFIED="2010-01-26 05:59:07 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Escobar Castro H, Bettas Ferrero G, Suarez Cortina L, Camarero Salces C, Lima M</AU>
<TI>Efficacy of cisapride in the treatment of gastroesophageal reflux (GER) in children. Evaluation of a double blind study</TI>
<TO>Efectividad del Cisapride en el tratamiento del reflujo gastroesofagico (R.G.E.) en ninos. Valoracion de un estudio a doble ciego</TO>
<SO>Anales Espanoles de Pediatria</SO>
<YR>1994</YR>
<VL>40</VL>
<NO>1</NO>
<PG>5-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greally-1992" MODIFIED="2010-01-12 09:02:30 -0500" MODIFIED_BY="[Empty name]" NAME="Greally 1992" YEAR="1992">
<REFERENCE MODIFIED="2010-01-12 09:02:30 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greally P, Hampton FJ, MacFadyen UM, Simpson H</AU>
<TI>Gaviscon and Carobel compared with cisapride in gastro-oesophageal reflux</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1992</YR>
<VL>67</VL>
<PG>618-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levy-2001" MODIFIED="2010-01-12 09:03:01 -0500" MODIFIED_BY="[Empty name]" NAME="Levy 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-01-12 09:03:01 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levy J, Hayes C, Kern J, Harris J, Flores A, Hyams J et al</AU>
<TI>Does cisapride influence cardiac rhythm? Results of a United States multicenter, double-blind, placebo-controlled pediatric study</TI>
<SO>Journal of Pediatric Gastroenterology and Nutrition</SO>
<YR>2001</YR>
<VL>32</VL>
<PG>458-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moya-1999" MODIFIED="2010-01-26 06:01:08 -0500" MODIFIED_BY="[Empty name]" NAME="Moya 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-01-26 06:01:08 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moya M, Juste M, Cortes E, Auxina A, Ortiz L</AU>
<TI>Clinical evaluation of the different therapeutic possibilities in the treatment of infant regurgitation.</TI>
<TO>Valoracion clinica de las distintas posibilidades terapeuticas en el manejo de las regurgitaciones del lactante</TO>
<SO>Revista Espanola de Pediatria</SO>
<YR>1999</YR>
<VL>55</VL>
<NO>3</NO>
<PG>219-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-07-16 06:35:31 -0400" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Orenstein-2000" MODIFIED="2010-03-02 05:06:48 -0500" MODIFIED_BY="[Empty name]" NAME="Orenstein 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-02-02 04:22:41 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Orenstein SR, Shalaby TM, Frankel EA, Kelsey SF</AU>
<TI>Cisapride, cimetidine, both or neither for infantile esophagitis: symptomatic and histologic results of 2-months randomized, double-blind, placebo-controlled therapy in 100 babies</TI>
<SO>Gastroenterology</SO>
<YR>2000</YR>
<VL>118</VL>
<NO>4</NO>
<PG>A20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-02-02 04:25:28 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Orenstein SR, Shalaby TM, Kelsey SF, Frankel E</AU>
<TI>Natural history of infant reflux esophagitis: symptoms and morphometric histology during one year without pharmacotherapy</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2006</YR>
<VL>101</VL>
<NO>3</NO>
<PG>628</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-03-02 05:04:55 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Orenstein SR, Shalaby TM, Kelsey SF, Frankel EA</AU>
<TI>Cimetidine, cisapride, both or neither for infant esophagitis: symptomatic response to 6m randomized, double blind, placebo-controlled therapy in 100 babies</TI>
<SO>Gastroenterology</SO>
<YR>2004</YR>
<VL>126 Suppl 2</VL>
<NO>4</NO>
<PG>A508</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-03-02 05:06:48 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Orenstein SR, Shalaby TM, Kelsey SF, Frankel EA</AU>
<TI>Cimetidine, cisapride, both or neither for infantile esophagitis: symptomatic response to 4m randomized, double-blind, placebo-controlled therapy in 100 babies [Abstracts: Poster session abstracts]</TI>
<SO>Journal of Pediatric Gastroenterology and Nutrition</SO>
<YR>2004</YR>
<VL>39 Suppl 1</VL>
<PG>P0791</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-02-02 04:30:56 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Orenstein SR</AU>
<TI>Personal communication</TI>
<TO>Additional data and details regarding completion of the study</TO>
<SO>Email</SO>
<YR>11.06.09</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Scott-1997" MODIFIED="2010-01-12 09:03:56 -0500" MODIFIED_BY="[Empty name]" NAME="Scott 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-01-12 09:03:56 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Scott RB, Ferreira C, Smith L, Jones AB, Machida H, Lohoues MJ et al</AU>
<TI>Cisapride in pediatric gastroesophageal reflux</TI>
<SO>Journal of Pediatric Gastroenterology and Nutrition</SO>
<YR>1997</YR>
<VL>25</VL>
<PG>499-506</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Eygen-1989_x0028_a_x0029_" MODIFIED="2010-01-12 09:04:24 -0500" MODIFIED_BY="[Empty name]" NAME="Van Eygen 1989(a)" YEAR="1989">
<REFERENCE MODIFIED="2010-01-12 09:04:24 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Eygen M, Van Ravensteyn H</AU>
<TI>Effect of cisapride on excessive regurgitation in infants</TI>
<SO>Clinical Therapeutics</SO>
<YR>1989</YR>
<VL>11</VL>
<NO>5</NO>
<PG>669-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Eygen-1989_x0028_b_x0029_" MODIFIED="2010-01-12 09:04:50 -0500" MODIFIED_BY="[Empty name]" NAME="Van Eygen 1989(b)" YEAR="1989">
<REFERENCE MODIFIED="2010-01-12 09:04:50 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Eygen M, Van Ravensteyn H</AU>
<TI>Effect of cisapride on excessive regurgitation in infants</TI>
<SO>Clinical Therapeutics</SO>
<YR>1989</YR>
<VL>11</VL>
<NO>5</NO>
<PG>669-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vandenplas-1991" MODIFIED="2010-01-12 09:05:23 -0500" MODIFIED_BY="[Empty name]" NAME="Vandenplas 1991" YEAR="1991">
<REFERENCE MODIFIED="2010-01-12 09:05:23 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vandenplas Y, De Roy C, Sacre L</AU>
<TI>Cisapride decreases prolonged episodes of reflux in infants</TI>
<SO>Journal of Pediatric Gastroenterology and Nutrition</SO>
<YR>1991</YR>
<VL>12</VL>
<PG>44-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2010-02-28 17:58:22 -0500" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Barnett-2001" MODIFIED="2010-01-12 09:29:30 -0500" MODIFIED_BY="[Empty name]" NAME="Barnett 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-01-12 09:29:30 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barnett CP, Omari T, Davidson GP, Goodchild L, Lontis R, Dent J et al</AU>
<TI>Effect of cisapride on gastric emptying in premature infants with feed intolerance</TI>
<SO>Journal of Paediatrics and Child Health</SO>
<YR>2001</YR>
<VL>37</VL>
<PG>559-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cucchiara-1990" MODIFIED="2010-01-12 09:29:55 -0500" MODIFIED_BY="[Empty name]" NAME="Cucchiara 1990" YEAR="1990">
<REFERENCE MODIFIED="2010-01-12 09:29:55 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cucchiara S, Staiano A, Boccieri A, De Stefano M, Capozzi C, Manzi G et al</AU>
<TI>Effects of cisapride on parameters of oesophageal motility and on the prolonged intraoesophageal pH test in infants with gastro-oesophageal reflux disease</TI>
<SO>Gut</SO>
<YR>1990</YR>
<VL>31</VL>
<PG>21-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Enriquez-1998" MODIFIED="2010-01-12 09:30:34 -0500" MODIFIED_BY="[Empty name]" NAME="Enriquez 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-01-12 09:30:34 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Enriquez A, Bolisetty S, Patole S, Garvey PA, Campbell PJ</AU>
<TI>Randomised controlled trial of cisapride in feed intolerance in preterm infants</TI>
<SO>Archives of Disease in Childhood. Fetal and Neonatal Edition</SO>
<YR>1998</YR>
<VL>79</VL>
<PG>F110-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heine-1996" MODIFIED="2010-02-28 17:57:18 -0500" MODIFIED_BY="[Empty name]" NAME="Heine 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-02-28 17:57:18 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heine RG, Catto-Smith AG, Reddihough DS</AU>
<TI>Effect of antireflux medication on salivary drooling in children with cerebral palsy</TI>
<SO>Developmental Medicine and Child Neurology</SO>
<YR>1996</YR>
<VL>38</VL>
<PG>1030-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McClure-1999" MODIFIED="2010-02-28 17:57:51 -0500" MODIFIED_BY="[Empty name]" NAME="McClure 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-02-28 17:57:51 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McClure RJ, Kristensen JH, Grauaug A</AU>
<TI>Randomised controlled trial of cisapride in preterm infants</TI>
<SO>Archives of Disease in Childhood. Fetal and Neonatal Edition</SO>
<YR>1999</YR>
<VL>80</VL>
<PG>F174-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pezzati-2001" MODIFIED="2010-02-28 17:58:09 -0500" MODIFIED_BY="[Empty name]" NAME="Pezzati 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-02-28 17:58:09 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pezzati M, Dani C, Biadaioli R, Gambi B, Lachina L, Rubaltelli FF</AU>
<TI>Randomised controlled trial of the effect of cisapride on the pyloric muscle in preterm infants</TI>
<SO>European Journal of Pediatrics</SO>
<YR>2001</YR>
<VL>160</VL>
<PG>572-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reddy-2000" MODIFIED="2010-02-28 17:58:22 -0500" MODIFIED_BY="[Empty name]" NAME="Reddy 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-02-28 17:58:22 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reddy PS, Deorari AK, Bal CS, Paul VK, Singh M</AU>
<TI>A double-blind placebo-controlled study on prophylactic use of cisapride on feed intolerance and gastric emptying in preterm neonates</TI>
<SO>Indian Pediatrics</SO>
<YR>2000</YR>
<VL>37</VL>
<PG>837-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saye-1987" MODIFIED="2010-01-26 06:03:40 -0500" MODIFIED_BY="[Empty name]" NAME="Saye 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-01-26 06:03:40 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saye ZN, Forget P, Geubelle F</AU>
<TI>Effect of Cisapride on gastroesophageal reflux in children with chronic bronchopulmonary disease: A double-blind cross-over pH-monitoring study</TI>
<SO>Pediatric Pulmonology</SO>
<YR>1987</YR>
<VL>3</VL>
<PG>8-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2010-01-26 06:17:08 -0500" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2010-03-02 07:06:15 -0500" MODIFIED_BY="Cathy Bennett">
<ADDITIONAL_REFERENCES MODIFIED="2010-03-02 07:06:15 -0500" MODIFIED_BY="Cathy Bennett">
<REFERENCE ID="REF-Breckenridge-2000" MODIFIED="2008-10-30 07:01:25 -0400" MODIFIED_BY="Karen Hovhannisyan" NAME="Breckenridge 2000" TYPE="OTHER">
<AU>Breckenridge A</AU>
<TI>Suspension of cisapride (Prepulsid) licences: Product withdrawal</TI>
<SO>Committee on Safety of Medicines, London</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Colson-1990" MODIFIED="2008-10-30 07:01:25 -0400" MODIFIED_BY="Karen Hovhannisyan" NAME="Colson 1990" TYPE="JOURNAL_ARTICLE">
<AU>Colson DJ, Campbell CA, Wright VA, Watson BW</AU>
<TI>Predictive value of oesophageal pH variables in children with gastro-oesophageal reflux</TI>
<SO>Gut</SO>
<YR>1990</YR>
<VL>31</VL>
<PG>370-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cucchiara-1996" MODIFIED="2010-02-28 18:01:42 -0500" MODIFIED_BY="[Empty name]" NAME="Cucchiara 1996" TYPE="JOURNAL_ARTICLE">
<AU>Cucchiara S, Campanozzi A, Greco L, Franco MT, Emiliano M, Alfieri E et al</AU>
<TI>Predictive value of esophageal manometry and gastroesophageal pH monitoring for responsiveness of reflux disease to medical therapy in children</TI>
<SO>American Journal of Gastroeneterology</SO>
<YR>1996</YR>
<VL>91</VL>
<NO>4</NO>
<PG>680-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Davidson-2009" MODIFIED="2010-02-07 05:35:13 -0500" MODIFIED_BY="[Empty name]" NAME="Davidson 2009" TYPE="CORRESPONDENCE">
<AU>Davidson GP</AU>
<TI>Personal communication</TI>
<TO>Clarification of trial characteristics and additional data</TO>
<SO>Meeting</SO>
<YR>14.9.99</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2010-02-28 17:59:13 -0500" MODIFIED_BY="[Empty name]" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Smith GD, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-EMEA-2002" MODIFIED="2010-03-02 07:06:15 -0500" MODIFIED_BY="Cathy Bennett" NAME="EMEA 2002" TYPE="UNPUBLISHED">
<AU>European Medicines Agency</AU>
<TI>Committee for proprietary medicinal products (CPMP) opinion following and article 31 referral. Cisapride</TI>
<SO>EMEA/CPMP/24844/02. http://www.emea.europa.eu/pdfs/human/referral/cisapride/2484402en.pdf</SO>
<YR>London 7 October 2002. Accessed 26/01/10</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hampton-1990" MODIFIED="2008-10-30 07:01:25 -0400" MODIFIED_BY="Karen Hovhannisyan" NAME="Hampton 1990" TYPE="JOURNAL_ARTICLE">
<AU>Hampton FJ, MacFayden UM, Simpson H</AU>
<TI>Reproducibility of 24 hour oesophageal pH studies in infants</TI>
<SO>Archives of Diseases in Childhood</SO>
<YR>1990</YR>
<VL>65</VL>
<PG>1249-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Henney-2000" MODIFIED="2010-03-02 05:09:24 -0500" MODIFIED_BY="[Empty name]" NAME="Henney 2000" TYPE="JOURNAL_ARTICLE">
<AU>Henney JE</AU>
<TI>Withdrawal of troglitazone and cisapride</TI>
<SO>JAMA</SO>
<YR>2000</YR>
<VL>283</VL>
<PG>2228</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2009" MODIFIED="2009-11-29 05:22:56 -0500" MODIFIED_BY="[Empty name]" NAME="Higgins 2009" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]</TI>
<SO>The Cochrane Collaboration,</SO>
<YR>2009. Available from www.cochrane-handbook.org</YR>
<IDENTIFIERS MODIFIED="2009-11-29 05:19:37 -0500" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Klausner-1998" MODIFIED="2010-03-02 05:09:49 -0500" MODIFIED_BY="[Empty name]" NAME="Klausner 1998" TYPE="CORRESPONDENCE">
<AU>Klausner MA</AU>
<TI>Jansen Pharmaceutical Research Foundation. Important safety and efficacy information</TI>
<SO>http://pharminfo.com/medwatch/mwrpt50.html (accessed June 2000)</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nelson-1997" MODIFIED="2010-02-28 18:00:02 -0500" MODIFIED_BY="[Empty name]" NAME="Nelson 1997" TYPE="JOURNAL_ARTICLE">
<AU>Nelson SP, Chen EH, Syniar GM, Kaufer Christoffel K</AU>
<TI>Prevalence of symptoms of gastroesophageal reflux during infancy</TI>
<SO>Archives of Pediatrics and Adolescent Medicine</SO>
<YR>1997</YR>
<VL>151</VL>
<PG>569-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Orenstein-2009" MODIFIED="2010-03-02 06:57:47 -0500" MODIFIED_BY="Cathy Bennett" NAME="Orenstein 2009" TYPE="CORRESPONDENCE">
<AU>Orenstein SR</AU>
<TI>Personal communication</TI>
<TO>Additional data and details regarding completion of the study</TO>
<SO>Email</SO>
<YR>11.06.09</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rudolph-1996" MODIFIED="2010-02-28 18:00:18 -0500" MODIFIED_BY="[Empty name]" NAME="Rudolph 1996" TYPE="BOOK_SECTION">
<AU>Rudolph CD</AU>
<TI>Gastroesophageal Reflux</TI>
<SO>Rudolph's Pediatrics</SO>
<YR>1996</YR>
<PG>1058-60</PG>
<ED>Rudolph AM, Hoffman JIE, Rudolph CD</ED>
<PB>Appleton and Lange</PB>
<CY>Stamford, Connecticut</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" MODIFIED="2010-02-28 18:00:32 -0500" MODIFIED_BY="[Empty name]" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shulman-2000" MODIFIED="2010-03-02 05:10:45 -0500" MODIFIED_BY="[Empty name]" NAME="Shulman 2000" TYPE="JOURNAL_ARTICLE">
<AU>Shulman RJ, Boyle JT, Colletti RB, Friedman R, Heyman MB, Kearns G et al; The North American Society for Pediatrics Gastroenterology and Nutrition.</AU>
<TI>An updated medical position statement of the North American Society for Pediatric Gastroenterology and Nutrition</TI>
<SO>Journal of Pediatric Gastroenterology and Nutrition</SO>
<YR>2000</YR>
<VL>31</VL>
<NO>2</NO>
<PG>232-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Treem-1991" MODIFIED="2010-02-28 18:00:50 -0500" MODIFIED_BY="[Empty name]" NAME="Treem 1991" TYPE="JOURNAL_ARTICLE">
<AU>Treem WR, Davis PM, Hyams JS</AU>
<TI>Gastroesophageal reflux in the older child: presentation, response to treatment and long-term follow-up</TI>
<SO>Clinical Pediatrics</SO>
<YR>1991</YR>
<VL>30</VL>
<NO>7</NO>
<PG>435-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vandenplas-1993" MODIFIED="2010-02-28 18:01:06 -0500" MODIFIED_BY="[Empty name]" NAME="Vandenplas 1993" TYPE="JOURNAL_ARTICLE">
<AU>Vandenplas Y, Ashkenazi A, Belli D, Boige N, Bouquet J, Cadranel S et al</AU>
<TI>A proposition for the diagnosis and treatment of gastro-oesophageal reflux disease in children: a report from a working group on gastro-oesophageal reflux disease</TI>
<SO>European Journal of Pediatrics</SO>
<YR>1993</YR>
<VL>152</VL>
<PG>704-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vandenplas-1999" MODIFIED="2010-01-26 06:14:57 -0500" MODIFIED_BY="[Empty name]" NAME="Vandenplas 1999" TYPE="JOURNAL_ARTICLE">
<AU>Vandenplas Y, Belli DC, Benatar A</AU>
<TI>The role of cisapride in the treatment of pediatric gastroesophageal reflux</TI>
<SO>Journal of Pediatric Gastroenterology and Nutrition</SO>
<YR>1999</YR>
<VL>28</VL>
<PG>518-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Varty-1993" MODIFIED="2010-02-28 18:01:21 -0500" MODIFIED_BY="[Empty name]" NAME="Varty 1993" TYPE="JOURNAL_ARTICLE">
<AU>Varty K, Evans D, Kapila L</AU>
<TI>Paediatric gastro-oesophageal reflux: prognostic indicators from pH monitoring</TI>
<SO>Gut</SO>
<YR>1993</YR>
<VL>34</VL>
<PG>1478-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ward-1999" MODIFIED="2008-10-30 07:01:25 -0400" MODIFIED_BY="Karen Hovhannisyan" NAME="Ward 1999" TYPE="JOURNAL_ARTICLE">
<AU>Ward RM, Lemons JA, Molteni RA</AU>
<TI>Cisapride: a survey of the frequency of use and adverse events in premature newborns</TI>
<SO>Pediatrics</SO>
<YR>1999</YR>
<VL>103</VL>
<PG>469-72</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2010-02-09 06:41:08 -0500" MODIFIED_BY="Cathy Bennett">
<REFERENCE ID="REF-Gilbert-RE-et-al" MODIFIED="2010-02-09 06:41:08 -0500" MODIFIED_BY="Cathy Bennett" NAME="Gilbert RE et al" TYPE="JOURNAL_ARTICLE">
<AU>Gilbert RE, Augood C, MacLennan S, Logan S</AU>
<TI>Cisapride treatment for gastro-oesophageal reflux: a systematic review of randomized controlled trials</TI>
<SO>Journal of Paediatrics and Child Health</SO>
<YR>2000</YR>
<VL>36</VL>
<PG>525-9</PG>
<IDENTIFIERS/>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2010-03-02 06:37:04 -0500" MODIFIED_BY="Cathy Bennett">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2010-03-02 06:37:04 -0500" MODIFIED_BY="Cathy Bennett" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2010-03-02 06:35:52 -0500" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Cohen-1999">
<CHAR_METHODS MODIFIED="2010-03-02 04:42:12 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-03-02 04:39:01 -0500" MODIFIED_BY="[Empty name]">
<P>Age &lt; 36 months<BR/>Clinical diagnosis of GOR: frequent V or R often associated with feeding difficulties and/or excessive crying.<BR/>Baseline 24-h oesophageal pH monitoring: RI &#8805;5% OR GOR score (Euler and Byrne) &#8805;50.<BR/>Exclusion criteria: anatomic abnormality of the GI tract, previous GI surgery, treatment with anticholinergics, theophylline, other diagnosis which could explain vomiting.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-02 04:39:30 -0500" MODIFIED_BY="[Empty name]">
<P>2 weeks of either:<BR/>cisapride suspension (1mg/ml) 0.2 mg/kg qid (n=50*)<BR/>placebo (n=45*)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-03-02 04:40:35 -0500" MODIFIED_BY="[Empty name]">
<P>Parental evaluation at 2 weeks:<BR/>overall symptom intensity on VAS 0-10 cm (0=absence of symptoms, 10= could not be worse)<BR/>improvement (marked=complete or near complete resolution of symptoms, moderate=partial resolution, minimal=slight improvement, unchanged, deterioration).<BR/>Evaluation during the 2 weeks of treatment:<BR/>presence of vomiting, gagging, crying (score 0-3).<BR/>AE: any, withdrawals due to AE.<BR/>Investigator assessment at 2 weeks:<BR/>24-h oesophageal pH<BR/>oesophagitis at biopsy.</P>
<P>Data (means, SD) also obtained for complications of GOR (apnoea, wheezing, nocturnal cough, haematemesis) and weight gain (<LINK REF="REF-Davidson-2009" TYPE="REFERENCE">Davidson 2009</LINK>).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-02 06:35:52 -0500" MODIFIED_BY="Cathy Bennett">
<P>68 participants (38, 30) completed the trial.<BR/>Withdrawn if: consent was withdrawn, serious AE, further investigations necessitated a change in treatment.<BR/>A high proportion of participants had received prior treatment with: thickened feeds, positional therapy, cisapride, H2 antagonists, antacids, metoclopramide, other.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-03-02 06:36:05 -0500" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Cucchiara-1987">
<CHAR_METHODS MODIFIED="2010-03-02 04:41:58 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-03-02 04:43:11 -0500" MODIFIED_BY="[Empty name]">
<P>Age 75 days - 47 months<BR/>Reflux oesophagitis in all (endoscopy and biopsy).<BR/>Diagnosis of GOR made by oesophageal pH (pH&lt;4 for &#8805;20min) and manometry.<BR/>Exclusion criteria: infections, neurologic, metabolic, renal disorders, abnormalities of the GI tract.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-02 04:43:23 -0500" MODIFIED_BY="[Empty name]">
<P>8 weeks of either:<BR/>cisapride syrup (1mg/ml) 0.3 mg/kg tid or<BR/>placebo syrup.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-03-02 04:43:36 -0500" MODIFIED_BY="[Empty name]">
<P>Assessed at 8 weeks by investigator:<BR/>24-h pH<BR/>LOS pressure<BR/>oesophagitis at biopsy.<BR/>Improvement at end of treatment: cured (clinical, pH-metric and histological variables normalised), improved (at least one of the three variables had improved), unchanged, worsened.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-02 06:36:05 -0500" MODIFIED_BY="Cathy Bennett">
<P>3 participants were withdrawn: 2 febrile URTI, 1 failed to take drug continuously.<BR/>Other outcomes measured: peristalsis amplitude, clinical score.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-03-02 04:45:36 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Escobar-Castro-1994">
<CHAR_METHODS MODIFIED="2010-02-28 17:54:15 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-03-02 04:45:25 -0500" MODIFIED_BY="[Empty name]">
<P>Age 3 months - 5 yrs<BR/>V and R present<BR/>GOR at oesophageal pH monitoring (RI &lt;3.5% considered normal).<BR/>No organic pathology to justify the reflux.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-02 04:45:36 -0500" MODIFIED_BY="[Empty name]">
<P>4 weeks of either:<BR/>cisapride 0.2 mg/kg (n=15)<BR/>placebo (n=15).<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Assessment at 2 and 4 weeks (probably by parents) of digestive symptoms: severe (R and/or V after each meal of an important part of the meal), moderate (R of a small quantity more than once a day), mild (R of a very small quantity once a day or sometime during the week), absent. <BR/>Investigator assessment at 4 weeks: 24-h oesophageal pH, AE, complications.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>1 drop-out in the cisapride group ('lack of motivation').<BR/>Other outcomes measured: radiological image, endoscopy, respiratory symptoms improvement (nil, slight, good, excellent).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-03-02 04:49:06 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Greally-1992">
<CHAR_METHODS MODIFIED="2010-03-02 04:49:06 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised study<BR/>Double-blind design was not feasible (see text for details).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-03-02 04:46:52 -0500" MODIFIED_BY="[Empty name]">
<P>Age 2-18 months<BR/>Chronic vomiting and GOR confirmed by 24h pH oesophageal monitoring (pH&lt;4 for &#8805;5% of the recording period).<BR/>No neurological, respiratory, metabolic, GI disease, treatment with H2 antagonists, theophylline, anticholinergic drugs.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-02 04:47:32 -0500" MODIFIED_BY="[Empty name]">
<P>4 weeks of either:<BR/>cisapride p.o. 0.2 mg/kg qid (n=26)<BR/>Gaviscon 1/2 sachet to each 90 ml feed qid (n=24, 21 also had Carobel).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-03-02 04:48:07 -0500" MODIFIED_BY="[Empty name]">
<P>Parental evaluation at 4 weeks of improvement (improved, not improved).<BR/>Investigator evaluation at 4 weeks of 24-h pH (RE was defined as pH&lt;4 for &#8805;15min).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>All 50 infants completed the study.<BR/>Other outcomes measured at 4 weeks: daily parental evaluation of severity of V: 0 (absent), 1(1-4 episodes/day), 2 (&gt;4 episodes/day), leading to a final symptoms score (range 0-1); improvement in diary scores.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-03-02 06:36:28 -0500" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Levy-2001">
<CHAR_METHODS MODIFIED="2010-03-02 04:49:27 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-03-02 06:29:43 -0500" MODIFIED_BY="Cathy Bennett">
<P>Age 6 months - 4 years (mean age 14.4 months)<BR/>Minimum 3 months of symptomatic GOR with failure to respond to at least 6 weeks of non-surgical treatment other than cisapride.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-06-10 10:05:13 -0400" MODIFIED_BY="Cathy Bennett">
<P>3-8 weeks of either cisapride 0.6 mg/kg/day or placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-03-02 06:36:28 -0500" MODIFIED_BY="Cathy Bennett">
<P>Data on QTc retained in 4 (68 participants) of 7 study centres (134 participants in total) in the trial. 19/68 excluded as ECGs recorded after 8 weeks of treatment. Mean QTc reported at 3-8 weeks of treatment and mean difference in QTc from baseline.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Data on symptoms of GOR not published "because efficacy results did not reach statistical significance".</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-03-02 04:51:52 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Moya-1999">
<CHAR_METHODS MODIFIED="2009-11-29 06:59:13 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial, unblinded</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-03-02 04:50:54 -0500" MODIFIED_BY="[Empty name]">
<P>Age 1-4 months, total 26 infants</P>
<P>No previous illness, with frequent regurgitation (&gt;5 regurgitations per day).</P>
<P>Exclusion criteria: receiving antireflux medication, breast fed.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-02 04:51:32 -0500" MODIFIED_BY="[Empty name]">
<P>Two weeks of either:</P>
<P>no treatment~original formula (n= 6)</P>
<P>carob bean gum with formula (n=8)</P>
<P>corn syrup with formula (n=6)</P>
<P>cisapride with formula (n=6).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-11-29 07:02:08 -0500" MODIFIED_BY="[Empty name]">
<P>Outcomes recorded by a daily diary by parents up to day 15</P>
<P>Mean daily number of regurgitations</P>
<P>Mean daily weight gain. No information on how daily means were calculated.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-02 04:51:52 -0500" MODIFIED_BY="[Empty name]">
<P>Cisapride dosage unclear - only noted as &#8220;usual dosage in 3 divided doses".</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-03-02 04:54:14 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Orenstein-2000">
<CHAR_METHODS MODIFIED="2010-01-26 06:32:17 -0500" MODIFIED_BY="[Empty name]">
<P>Multicentre, randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-03-02 04:52:09 -0500" MODIFIED_BY="[Empty name]">
<P>96 children &gt; 2 months old with biopsy-proven oesophagitis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-02 04:52:28 -0500" MODIFIED_BY="[Empty name]">
<P>1. cisapride 0.2 mg/kg qid and placebo<BR/>2. cimetidine 10 mg/kg qid and placebo<BR/>3. cisapride + cimetidine<BR/>4. placebo + placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-03-02 04:53:21 -0500" MODIFIED_BY="[Empty name]">
<P>Measured at 2, 6 and 12 months. Initial findings reported for 2 months.<BR/>1.Symptoms measured by parents using the Infant Gastroesophageal Reflux Questionnaire<BR/>2. Vomiting<BR/>3. Crying<BR/>4. Biopsy measuring histological parameters of papillary height and basal layer thickness</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-02 04:54:14 -0500" MODIFIED_BY="[Empty name]">
<P>Trial finished but only published as an abstract. Personal communication provided by Dr SR Orenstein, Academic Hospital of Pittsburgh, USA (<LINK REF="REF-Orenstein-2009" TYPE="REFERENCE">Orenstein 2009</LINK>).</P>
<P>Cisapride versus no cisapride: symptom questionnaire showed 86% with cisapride were well or better at 2 months compared with 70% for no cisapride groups (if 3 lost to follow up in cisapride group and 8 given no cisapride were assumed to have worse symptoms). No significant improvement in vomiting (frequency or volume). This paper was never published in article form as cisapride was taken off the market in the US amid concerns about its toxicity. 100 infants were enrolled, and nearly all of them completed the 12 months of the protocol, although follow up was discontinued for the last few infants in concordance with the<BR/>wishes of the FDA and the company.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-03-02 06:36:39 -0500" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Scott-1997">
<CHAR_METHODS MODIFIED="2010-02-28 17:54:37 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-03-02 04:56:01 -0500" MODIFIED_BY="[Empty name]">
<P>Age 6 weeks - 2 years<BR/>Daily R or V during a 1 week baseline period<BR/>AND &#8805;1 episode of GOR (pH&lt;4 for &gt;20min) at 18-h pH monitoring.<BR/>Exclusion criteria: not meeting the inclusion criteria, premature, previous GI surgery (excluding for appendicitis), illnesses and drugs that could interfere with cisapride, reflux due to known anatomic abnormalities, underlying disease, infection of the GI tract; parents who couldn't express concern, comply with study, complete diaries.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-02 04:56:16 -0500" MODIFIED_BY="[Empty name]">
<P>6 weeks of positioning and thickened feeds (where appropriate) and either:<BR/>cisapride suspension (1mg/ml) 0.2 mg/kg qid (n=23) or<BR/>placebo suspension (n=26).<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-27 04:49:43 -0500" MODIFIED_BY="[Empty name]">
<P>Assessed at 2, 4, 6 weeks by parent and investigator: global evaluation of condition on VAS 0-100 mm (0=the worst it's ever been, 100=completely recovered); any AE, specific AE.<BR/>Assessed at 6 weeks by parent and investigator: global evaluation of overall treatment (deterioration=symptoms worse, poor=no improvement, fair=slight improvement, persistence of some symptoms, good=improvement, occasional symptoms, excellent=complete relief of symptoms).<BR/>Assessed at 6 weeks by investigator: 24-h pH, LOS pressure, oesophagitis at biopsy.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-02 06:36:39 -0500" MODIFIED_BY="Cathy Bennett">
<P>45 participants (21 cisapride, 24 placebo) were evaluated (4 were non-compliant or had violated protocol).<BR/>Other outcomes: various at 24-h pH, swallow pressure, daily diary recording of each episode (none, mild, moderate, severe), score for R and V.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-03-02 06:36:53 -0500" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Van-Eygen-1989_x0028_a_x0029_">
<CHAR_METHODS MODIFIED="2010-03-02 04:57:40 -0500" MODIFIED_BY="[Empty name]">
<P>Three trials:<BR/>I open trial (n=69)<BR/>II (Van Eygen 1989a) randomised, double-blind, placebo-controlled trial (n=23)<BR/>III (Van Eygen 1989b) dose-response trial (n=50).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-03-02 04:57:44 -0500" MODIFIED_BY="[Empty name]">
<P>Age 5 days - 12 months<BR/>Excessive R or V at least twice a day in all children.<BR/>In trial II: GOR at radiology or pH monitoring in all children.<BR/>In trial III: GOR at radiology, endoscopy or pH monitoring in 16 children.<BR/>Non-pharmacologic measures (e.g. positioning, food thickening) had failed to improve the reflux.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-02 04:58:53 -0500" MODIFIED_BY="[Empty name]">
<P>4 weeks of either<BR/>Trial II: cisapride oral suspension 0.15 mg/kg tid (n=12)<BR/>placebo oral suspension (n=11).<BR/>Trial III: cisapride 0.1 mg/kg tid (n=14) (not used in the analysis)<BR/>cisapride 0.2 mg/kg tid (n=14)<BR/>placebo tid (n=17).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Assessed at 2 and 4 weeks by the investigator: AE, global therapeutic result (poor=no change, fair=distinct but slight improvement, good=marked reduction in R, excellent=virtually complete symptomatic cure).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-02 06:36:53 -0500" MODIFIED_BY="Cathy Bennett">
<P>In trial III: analysis based on 45 of 50 participants. There were 4 early drop-outs and 1 protocol violation and a further 10 drop-outs (4 in the cisapride 0.2 mg/kg group and 6 in the placebo group.<BR/>Other outcomes assessed at 2 and 4 weeks by investigator: severity of R (severe=the major part of the meal is R, moderate=effortless R of a mouthful of feeding, slight=R of rather excessive saliva only, no R); frequency of R (after each meal, at least twice a day, once a day or several times a week, never).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-09 06:39:42 -0500" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Van-Eygen-1989_x0028_b_x0029_">
<CHAR_METHODS MODIFIED="2010-02-09 06:39:42 -0500" MODIFIED_BY="Cathy Bennett">
<P>Trial III referred to above. Please see above for details.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-03-02 05:00:55 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vandenplas-1991">
<CHAR_METHODS MODIFIED="2010-03-02 04:59:45 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-03-02 04:59:49 -0500" MODIFIED_BY="[Empty name]">
<P>Age 2 - 4 months<BR/>Pathological GOR of V and R for &gt; 2 weeks, &gt;6 times/day AND abnormal oesophageal pH monitoring.<BR/>Exclusion criteria: reflux secondary to diseases (e.g. infections, allergy, pyloric stenosis).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-02 05:00:18 -0500" MODIFIED_BY="[Empty name]">
<P>13-16 days of positional therapy and either:<BR/>cisapride (1 mg/ml) 0.2 mg/kg qid (n=21) or<BR/>placebo (n=21).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Parental evaluation of GOR severity at 2 weeks: 0 (no V at all), 1 (1-3 episodes of V or R/day), 2 (4-6 episodes of V or R/day), 3 (&gt;6 episodes of V or R/day). NB: all had grade 3 at the beginning.<BR/>Investigator evaluation at 2 weeks: 24-h pH.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-02 05:00:55 -0500" MODIFIED_BY="[Empty name]">
<P>None of the infants received milk-thickening products.<BR/>29 completed the study, 13 exclusions post-randomisation: unexpected weaning (3,3), withdrawal of permission for second pH monitoring because symptoms had improved (4,1), lack of improvement and parents refused to continue (0,2).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>* Number of participants in brackets represents number randomised to respective treatment group.<BR/>AE = adverse events, GI = gastrointestinal, GOR = gastro-oesophageal reflux, LOS = lower oesophageal sphincter, R = regurgitation, RE = reflux episode, RI = reflux index (percentage of time in 24 h during which pH &lt; 4), URTI = upper respiratory tract infection, V = vomiting, VAS = visual analogue scale</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2010-03-02 05:03:12 -0500" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Barnett-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study participants were preterm neonates.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-02 05:01:37 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cucchiara-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-02 05:01:37 -0500" MODIFIED_BY="[Empty name]">
<P>Cisapride given intravenously in a single dose over 5 minutes. No mention of study being randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-01-27 04:50:00 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Enriquez-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-01-27 04:50:00 -0500" MODIFIED_BY="[Empty name]">
<P>Cisapride was administered prophylactically during the introduction of enteral feeding by nasogastric tube to preterm infants of less than 33 weeks gestation at birth.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Heine-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>The outcomes reported by this study (i.e. drooling) are not relevant to the review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-02 05:02:22 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McClure-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-02 05:02:22 -0500" MODIFIED_BY="[Empty name]">
<P>The outcomes reported in this study (i.e. half gastric emptying time, whole gastrointestinal transit time) are not relevant to the review. Cisapride was prescribed for clinically diagnosed gastro-oesophageal reflux or poor feed tolerance in very preterm infants (less than 32 weeks of gestation).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-29 07:05:06 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pezzati-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-29 07:05:06 -0500" MODIFIED_BY="[Empty name]">
<P>Study participants were preterm neonates less than 34 weeks gestation. Cisapride was administered for feed intolerance by naso-gastric tube.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-02 05:02:50 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Reddy-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-02 05:02:50 -0500" MODIFIED_BY="[Empty name]">
<P>Preterm neonates less than 34 weeks gestation. Cisapride administered prophylactically during the introduction of enteral feeding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-02 05:03:12 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Saye-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-02 05:03:12 -0500" MODIFIED_BY="[Empty name]">
<P>All infants and children were suspected of having GOR (only 5 of them had digestive symptoms) and cisapride treatment was given for only 16 hours.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2010-01-26 06:17:08 -0500" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2010-03-02 06:32:34 -0500" MODIFIED_BY="Cathy Bennett">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2010-03-02 06:32:34 -0500" MODIFIED_BY="Cathy Bennett" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-02 04:41:29 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cohen-1999">
<DESCRIPTION>
<P>Further details obtained from one of the trial investigators (GD) by one of the review authors (SM). Randomisation was centrally controlled (outside of the three participating centres), by computer generated code (<LINK REF="REF-Davidson-2009" TYPE="REFERENCE">Davidson 2009</LINK>).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-02 03:44:58 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cucchiara-1987">
<DESCRIPTION>
<P>Details not given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-02 03:45:17 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Escobar-Castro-1994">
<DESCRIPTION>
<P>Details not given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-02 03:44:04 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Greally-1992">
<DESCRIPTION>
<P>Details not given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-02 03:46:21 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Levy-2001">
<DESCRIPTION>
<P>Details not given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-02 03:47:21 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moya-1999">
<DESCRIPTION>
<P>Details not given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-02 06:32:29 -0500" MODIFIED_BY="Cathy Bennett" RESULT="UNKNOWN" STUDY_ID="STD-Orenstein-2000">
<DESCRIPTION>
<P>"randomised, double-blind in blocks of 8" pA20. Further details not given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-02 06:32:34 -0500" MODIFIED_BY="Cathy Bennett" RESULT="YES" STUDY_ID="STD-Scott-1997">
<DESCRIPTION>
<P>"randomisation code for the allocation of patients to cisapride or placebo suspension was generated by computer" (p501).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-02 04:59:29 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-Eygen-1989_x0028_a_x0029_">
<DESCRIPTION>
<P>Details not given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-02 03:59:45 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-Eygen-1989_x0028_b_x0029_">
<DESCRIPTION>
<P>Details not given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-02 04:00:03 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vandenplas-1991">
<DESCRIPTION>
<P>Details not given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2010-03-02 05:01:09 -0500" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-09 06:11:39 -0500" MODIFIED_BY="Cathy Bennett" RESULT="YES" STUDY_ID="STD-Cohen-1999">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-09 06:12:04 -0500" MODIFIED_BY="Cathy Bennett" RESULT="UNKNOWN" STUDY_ID="STD-Cucchiara-1987">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-02 04:48:41 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Escobar-Castro-1994">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-09 06:38:26 -0500" MODIFIED_BY="Cathy Bennett" RESULT="UNKNOWN" STUDY_ID="STD-Greally-1992">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-09 06:38:32 -0500" MODIFIED_BY="Cathy Bennett" RESULT="UNKNOWN" STUDY_ID="STD-Levy-2001">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-27 04:35:11 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moya-1999">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-02 04:32:04 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Orenstein-2000">
<DESCRIPTION>
<P>Unclear - details not given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-02 04:57:11 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Scott-1997">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-09 06:39:20 -0500" MODIFIED_BY="Cathy Bennett" RESULT="UNKNOWN" STUDY_ID="STD-Van-Eygen-1989_x0028_a_x0029_">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-09 06:39:52 -0500" MODIFIED_BY="Cathy Bennett" RESULT="UNKNOWN" STUDY_ID="STD-Van-Eygen-1989_x0028_b_x0029_">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-02 05:01:09 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vandenplas-1991">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2010-03-02 06:32:34 -0500" MODIFIED_BY="Cathy Bennett" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-02 04:41:49 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cohen-1999">
<DESCRIPTION>
<P>"matched placebo (both provided by Janssen Research Foundation, Belgium)" p288. Further details not given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-02-02 03:45:07 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cucchiara-1987">
<DESCRIPTION>
<P>"placebo syrup, which was identical to cisapride in taste and appearance" p454. Further details not given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-02-02 03:45:32 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Escobar-Castro-1994">
<DESCRIPTION>
<P>Details not given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-02-02 03:46:08 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Greally-1992">
<DESCRIPTION>
<P>Double-blind design was not feasible (see text of review for details).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-02-02 03:46:55 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Levy-2001">
<DESCRIPTION>
<P>"blindly assigned to receive either placebo or cisapride" p459. Further details not given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-02-02 03:48:21 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Moya-1999">
<DESCRIPTION>
<P>Blinding not feasible, due to nature of different interventions (see above).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-02 04:54:56 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Orenstein-2000">
<DESCRIPTION>
<P>"blindly assigned to 1 of 4 arms", "At any visit with both Sx &amp; Bx unimproved, infants were rescued to un-masked Cm-Cs, without un-masking prior Rx." P0791. Further details not given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-02-02 03:58:24 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Scott-1997">
<DESCRIPTION>
<P>"matching suspension of placebo" p500. "The double-blind code was to be broken only in the event of an emergency." p501. Further details not given. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-02-02 03:59:31 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-Eygen-1989_x0028_a_x0029_">
<DESCRIPTION>
<P>"under double-blind conditions, the medications being identical in appearance and taste" p670. Further details not given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-02-02 03:59:49 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-Eygen-1989_x0028_b_x0029_">
<DESCRIPTION>
<P>"under double-blind conditions, the medications being identical in appearance and taste" p670. Further details not given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-02 06:32:34 -0500" MODIFIED_BY="Cathy Bennett" RESULT="UNKNOWN" STUDY_ID="STD-Vandenplas-1991">
<DESCRIPTION>
<P>"Both products (cisapride, 1mg/ml, and placebo) were prepared in the same way and could not be recognised by taste or aspect." p45. "The randomisation code was broken after the second pH monitoring" p45. Further details not given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2010-03-02 05:41:49 -0500" MODIFIED_BY="Cathy Bennett">
<COMPARISON ID="CMP-001" MODIFIED="2010-02-12 06:07:17 -0500" MODIFIED_BY="Cathy Bennett" NO="1">
<NAME>Main analysis for cisapride versus no treatment</NAME>
<DICH_OUTCOME CHI2="24.23014986339045" CI_END="1.188979760356657" CI_START="0.0991470701063646" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="OR" EFFECT_SIZE="0.3433421903220315" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="64" I2="75.2374622780792" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.07517446181782228" LOG_CI_START="-1.0037201150990125" LOG_EFFECT_SIZE="-0.464272826640595" METHOD="MH" MODIFIED="2010-02-12 06:07:17 -0500" MODIFIED_BY="Cathy Bennett" NO="1" P_CHI2="4.737191914709893E-4" P_Q="0.0" P_Z="0.09163527867120212" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="USER" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="1.974964758170152" TOTALS="YES" TOTAL_1="123" TOTAL_2="113" WEIGHT="100.0" Z="1.6868339848673048">
<NAME>'Worse, same or slight improvement' versus 'moderate or excellent improvement'</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.81570581742668" CI_START="0.34326457785436854" EFFECT_SIZE="1.2857142857142858" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.6826599488123608" LOG_CI_START="-0.4643710099622247" LOG_EFFECT_SIZE="0.10914446942506809" MODIFIED="2010-02-12 06:07:17 -0500" MODIFIED_BY="Cathy Bennett" ORDER="48" O_E="0.0" SE="0.6737716630790093" STUDY_ID="STD-Scott-1997" TOTAL_1="20" TOTAL_2="16" VAR="0.45396825396825397" WEIGHT="16.535513520957746"/>
<DICH_DATA CI_END="0.897177368730331" CI_START="0.010109812285408637" EFFECT_SIZE="0.09523809523809523" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="-0.04712169001494833" LOG_CI_START="-1.995256908124928" LOG_EFFECT_SIZE="-1.021189299069938" MODIFIED="2010-02-12 05:27:19 -0500" MODIFIED_BY="Cathy Bennett" ORDER="49" O_E="0.0" SE="1.1443442705426587" STUDY_ID="STD-Cucchiara-1987" TOTAL_1="8" TOTAL_2="9" VAR="1.3095238095238095" WEIGHT="12.22828267961186"/>
<DICH_DATA CI_END="1.0319766906208623" CI_START="0.019775798669471947" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.013669887941326793" LOG_CI_START="-1.7038659679698407" LOG_EFFECT_SIZE="-0.8450980400142569" MODIFIED="2009-11-29 05:38:41 -0500" MODIFIED_BY="[Empty name]" ORDER="50" O_E="0.0" SE="1.008889063701824" STUDY_ID="STD-Van-Eygen-1989_x0028_b_x0029_" TOTAL_1="10" TOTAL_2="11" VAR="1.0178571428571428" WEIGHT="13.419994905119129"/>
<DICH_DATA CI_END="4.005669527767448" CI_START="0.07101046216435611" EFFECT_SIZE="0.5333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6026751166532062" LOG_CI_START="-1.1486776607806815" LOG_EFFECT_SIZE="-0.27300127206373764" MODIFIED="2009-11-29 05:38:41 -0500" MODIFIED_BY="[Empty name]" ORDER="51" O_E="0.0" SE="1.028753290800731" STUDY_ID="STD-Van-Eygen-1989_x0028_a_x0029_" TOTAL_1="12" TOTAL_2="11" VAR="1.0583333333333333" WEIGHT="13.240919109208853"/>
<DICH_DATA CI_END="1.5827376296340077" CI_START="0.13054063186436707" EFFECT_SIZE="0.45454545454545453" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.19940892784652764" LOG_CI_START="-0.88425428949094" LOG_EFFECT_SIZE="-0.3424226808222063" MODIFIED="2009-11-29 05:38:41 -0500" MODIFIED_BY="[Empty name]" ORDER="52" O_E="0.0" SE="0.6365491380834674" STUDY_ID="STD-Vandenplas-1991" TOTAL_1="21" TOTAL_2="21" VAR="0.4051948051948052" WEIGHT="16.87435383825014"/>
<DICH_DATA CI_END="0.09717544491768539" CI_START="3.106709792244721E-4" EFFECT_SIZE="0.005494505494505495" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="14" LOG_CI_END="-1.0124434622752572" LOG_CI_START="-3.5076993136948924" LOG_EFFECT_SIZE="-2.2600713879850747" MODIFIED="2010-02-12 05:27:27 -0500" MODIFIED_BY="Cathy Bennett" ORDER="53" O_E="0.0" SE="1.465725638839564" STUDY_ID="STD-Escobar-Castro-1994" TOTAL_1="14" TOTAL_2="15" VAR="2.1483516483516483" WEIGHT="9.74061912886163"/>
<DICH_DATA CI_END="6.684470738895967" CI_START="0.9013119547928236" EFFECT_SIZE="2.4545454545454546" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="15" LOG_CI_END="0.8250670265155153" LOG_CI_START="-0.04512486851399071" LOG_EFFECT_SIZE="0.3899710790007623" MODIFIED="2010-02-12 06:07:15 -0500" MODIFIED_BY="Cathy Bennett" ORDER="54" O_E="0.0" SE="0.511155026659683" STUDY_ID="STD-Cohen-1999" TOTAL_1="38" TOTAL_2="30" VAR="0.2612794612794613" WEIGHT="17.96031681799064"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.2976058066019016" CI_START="-4.097605806601902" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.9000000000000004" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2010-02-09 06:52:48 -0500" MODIFIED_BY="Cathy Bennett" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.5811863872866019" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="6" TOTAL_2="6" UNITS="" WEIGHT="100.0" Z="0.5516526091002503">
<NAME>Mean daily regurgitations</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.2976058066019016" CI_START="-4.097605806601902" EFFECT_SIZE="-0.9000000000000004" ESTIMABLE="YES" MEAN_1="-7.0" MEAN_2="-6.1" MODIFIED="2009-10-23 08:46:21 -0400" MODIFIED_BY="[Empty name]" ORDER="43" SD_1="3.4" SD_2="2.1" SE="1.6314615124687026" STUDY_ID="STD-Moya-1999" TOTAL_1="6" TOTAL_2="6" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="7.047904716642421" CI_START="-7.647904716642422" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.3000000000000007" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.03" MODIFIED="2010-02-09 06:52:56 -0500" MODIFIED_BY="Cathy Bennett" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.9362202820431296" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="6" TOTAL_2="6" UNITS="" WEIGHT="99.99999999999999" Z="0.08002134187046121">
<NAME>Mean daily weight gain</NAME>
<GROUP_LABEL_1>Favours experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="7.047904716642421" CI_START="-7.647904716642422" EFFECT_SIZE="-0.3000000000000007" ESTIMABLE="YES" MEAN_1="6.6" MEAN_2="6.9" MODIFIED="2009-10-23 08:05:40 -0400" MODIFIED_BY="[Empty name]" ORDER="44" SD_1="5.7" SD_2="7.2" SE="3.7489998666310993" STUDY_ID="STD-Moya-1999" TOTAL_1="6" TOTAL_2="6" WEIGHT="99.99999999999999"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="6.457849891244541" CI_END="-2.8494333363695" CI_START="-10.126681361755477" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-6.488057349062489" ESTIMABLE="YES" I2="38.05987956729775" I2_Q="0.0" ID="CMP-001.04" MODIFIED="2009-12-23 11:15:30 -0500" MODIFIED_BY="Cathy Bennett" NO="4" P_CHI2="0.16746569234808628" P_Q="1.0" P_Z="4.743704461868372E-4" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="USER" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="6.089058048158066" TOTALS="YES" TOTAL_1="92" TOTAL_2="84" UNITS="" WEIGHT="100.00000000000003" Z="3.494826255593628">
<NAME>Reflux index</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.8549392999421177" CI_START="-6.654939299942118" EFFECT_SIZE="-2.9000000000000004" ESTIMABLE="YES" MEAN_1="7.1" MEAN_2="10.0" ORDER="2" SD_1="7.9" SD_2="7.8" SE="1.915820560765708" STUDY_ID="STD-Cohen-1999" TOTAL_1="38" TOTAL_2="30" WEIGHT="35.314566883001774"/>
<CONT_DATA CI_END="1.4108352318521176" CI_START="-13.410835231852118" EFFECT_SIZE="-6.0" ESTIMABLE="YES" MEAN_1="12.5" MEAN_2="18.5" ORDER="2" SD_1="8.61" SD_2="11.62" SE="3.781107862342288" STUDY_ID="STD-Vandenplas-1991" TOTAL_1="14" TOTAL_2="15" WEIGHT="16.906343233325984"/>
<CONT_DATA CI_END="-5.395436990909241" CI_START="-13.784563009090759" EFFECT_SIZE="-9.59" ESTIMABLE="YES" MEAN_1="3.83" MEAN_2="13.42" ORDER="4" SD_1="3.47" SD_2="7.47" SE="2.1401224931564746" STUDY_ID="STD-Escobar-Castro-1994" TOTAL_1="14" TOTAL_2="15" WEIGHT="32.303311350532454"/>
<CONT_DATA CI_END="7.624494373360889" CI_START="-17.62449437336089" EFFECT_SIZE="-5.0" ESTIMABLE="YES" MEAN_1="15.0" MEAN_2="20.0" ORDER="6" SD_1="20.0" SD_2="17.0" SE="6.441186916158301" STUDY_ID="STD-Scott-1997" TOTAL_1="18" TOTAL_2="15" WEIGHT="7.243900608883033"/>
<CONT_DATA CI_END="-0.296423868468068" CI_START="-23.743576131531935" EFFECT_SIZE="-12.020000000000001" ESTIMABLE="YES" MEAN_1="11.83" MEAN_2="23.85" ORDER="8" SD_1="11.07" SD_2="13.57" SE="5.981526305588269" STUDY_ID="STD-Cucchiara-1987" TOTAL_1="8" TOTAL_2="9" WEIGHT="8.231877924256775"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.1678735200176969" CI_END="3.930823230171396" CI_START="0.8804338042520745" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="1.8603305218111728" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="45" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.5944835139581488" LOG_CI_START="-0.055303291063829634" LOG_EFFECT_SIZE="0.26959011144715955" METHOD="MH" MODIFIED="2009-10-23 08:57:07 -0400" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.6820088904364457" P_Q="0.0" P_Z="0.10387749568233597" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="USER" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="95" TOTAL_2="95" WEIGHT="100.0" Z="1.6263393006470792">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.7604461008453605" CI_START="0.7896765424970625" EFFECT_SIZE="2.1328125" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="32" LOG_CI_END="0.7604561173873682" LOG_CI_START="-0.10255076260159289" LOG_EFFECT_SIZE="0.3289526773928877" ORDER="2" O_E="0.0" SE="0.5069345132584688" STUDY_ID="STD-Cohen-1999" TOTAL_1="50" TOTAL_2="45" VAR="0.2569826007326007" WEIGHT="56.69088804578484"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="4" O_E="0.0" SE="0.0" STUDY_ID="STD-Escobar-Castro-1994" TOTAL_1="14" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.84810512085294" CI_START="0.4991131640301643" EFFECT_SIZE="1.5555555555555556" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.6855720280128942" LOG_CI_START="-0.30180097553506785" LOG_EFFECT_SIZE="0.19188552623891314" ORDER="6" O_E="0.0" SE="0.5799877898592662" STUDY_ID="STD-Scott-1997" TOTAL_1="23" TOTAL_2="26" VAR="0.33638583638583636" WEIGHT="43.30911195421516"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-16 11:52:29 -0400" MODIFIED_BY="[Empty name]" ORDER="8" O_E="0.0" SE="0.0" STUDY_ID="STD-Cucchiara-1987" TOTAL_1="8" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2010-02-12 06:47:37 -0500" MODIFIED_BY="Cathy Bennett" NO="2">
<NAME>Main analysis for cisapride versus Gaviscon</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="11.379848417237874" CI_START="0.9322601850975935" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="3.257142857142857" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="1.0561364771736756" LOG_CI_START="-0.030462863201281547" LOG_EFFECT_SIZE="0.5128368069861969" METHOD="MH" MODIFIED="2010-02-12 06:47:37 -0500" MODIFIED_BY="Cathy Bennett" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.06430365988638533" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="26" TOTAL_2="24" WEIGHT="100.0" Z="1.850068621047786">
<NAME>'Worse, same or slight improvement' versus 'moderate or excellent improvement'</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="11.379848417237868" CI_START="0.9322601850975936" EFFECT_SIZE="3.257142857142857" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="5" LOG_CI_END="1.0561364771736752" LOG_CI_START="-0.030462863201281495" LOG_EFFECT_SIZE="0.5128368069861969" ORDER="695" O_E="0.0" SE="0.6382738312897319" STUDY_ID="STD-Greally-1992" TOTAL_1="26" TOTAL_2="24" VAR="0.4073934837092732" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2010-03-02 05:41:49 -0500" MODIFIED_BY="Cathy Bennett" NO="3">
<NAME>Main analysis for cisapride versus dietary interventions</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.01" MODIFIED="2010-03-02 05:41:49 -0500" MODIFIED_BY="Cathy Bennett" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>'Worse, same or slight improvement' versus 'moderate or excellent improvement'</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="3.306698037942428" CI_START="-2.706698037942428" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.2999999999999998" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.02" MODIFIED="2009-10-23 08:41:47 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.8449547463587247" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="6" TOTAL_2="6" UNITS="" WEIGHT="100.0" Z="0.19555977618703416">
<NAME>Carob bean: mean daily regurgitations</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.306698037942428" CI_START="-2.706698037942428" EFFECT_SIZE="0.2999999999999998" ESTIMABLE="YES" MEAN_1="-7.0" MEAN_2="-7.3" MODIFIED="2009-10-23 08:41:47 -0400" MODIFIED_BY="[Empty name]" ORDER="46" SD_1="3.4" SD_2="1.6" SE="1.5340577998671803" STUDY_ID="STD-Moya-1999" TOTAL_1="6" TOTAL_2="6" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="7.316147428974097" CI_START="-2.116147428974098" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="2.5999999999999996" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.03" MODIFIED="2009-10-23 08:42:56 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.27990931110179795" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="6" TOTAL_2="6" UNITS="" WEIGHT="100.0" Z="1.0805231254003973">
<NAME>Carob bean: mean daily weight gain</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="7.316147428974097" CI_START="-2.116147428974098" EFFECT_SIZE="2.5999999999999996" ESTIMABLE="YES" MEAN_1="6.6" MEAN_2="4.0" MODIFIED="2009-10-23 08:42:56 -0400" MODIFIED_BY="[Empty name]" ORDER="45" SD_1="5.7" SD_2="1.5" SE="2.406241883103193" STUDY_ID="STD-Moya-1999" TOTAL_1="6" TOTAL_2="6" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.5073818788669957" CI_START="-3.1073818788669954" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.2999999999999998" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.04" MODIFIED="2009-11-05 12:42:45 -0500" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.834101673829991" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="6" TOTAL_2="8" UNITS="" WEIGHT="100.0" Z="0.20944396620502403">
<NAME>Corn syrup: mean daily regurgitations</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.5073818788669957" CI_START="-3.1073818788669954" EFFECT_SIZE="-0.2999999999999998" ESTIMABLE="YES" MEAN_1="-7.0" MEAN_2="-6.7" MODIFIED="2009-10-23 08:45:55 -0400" MODIFIED_BY="[Empty name]" ORDER="48" SD_1="3.4" SD_2="1.0" SE="1.4323640133243598" STUDY_ID="STD-Moya-1999" TOTAL_1="6" TOTAL_2="8" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.6579674342602183E-32" CI_END="3.059745015320964" CI_START="-10.459745015320966" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.7000000000000006" ESTIMABLE="YES" I2="100.00000000000001" I2_Q="0.0" ID="CMP-003.05" MODIFIED="2009-11-05 12:43:03 -0500" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="1.0" P_Z="0.2833600610801428" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="6" TOTAL_2="8" UNITS="" WEIGHT="100.00000000000001" Z="1.0728018181694492">
<NAME>Corn syrup: mean daily weight gain</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.0597450153209635" CI_START="-10.459745015320966" EFFECT_SIZE="-3.700000000000001" ESTIMABLE="YES" MEAN_1="6.6" MEAN_2="10.3" MODIFIED="2009-10-23 08:44:50 -0400" MODIFIED_BY="[Empty name]" ORDER="49" SD_1="5.7" SD_2="7.2" SE="3.448912872196107" STUDY_ID="STD-Moya-1999" TOTAL_1="6" TOTAL_2="8" WEIGHT="100.00000000000001"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2010-02-12 06:47:17 -0500" MODIFIED_BY="Cathy Bennett" NO="4">
<NAME>Sensitivity analyses for cisapride versus no treatment</NAME>
<DICH_OUTCOME CHI2="16.804202851052942" CI_END="0.5417748053122483" CI_START="0.07773553825444782" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="OR" EFFECT_SIZE="0.20521977512814474" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="102" I2="64.29464668343941" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="-0.2661811952575962" LOG_CI_START="-1.1093803899599723" LOG_EFFECT_SIZE="-0.6877807926087843" METHOD="MH" MODIFIED="2010-02-12 06:08:10 -0500" MODIFIED_BY="Cathy Bennett" NO="1" P_CHI2="0.010030436617005867" P_Q="0.0" P_Z="0.0013866902798199846" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.9987873980430875" TOTALS="YES" TOTAL_1="151" TOTAL_2="151" WEIGHT="100.0" Z="3.1974071873904997">
<NAME>Best case scenario</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3497604996594794" CI_START="0.25524376991252457" EFFECT_SIZE="0.5869565217391305" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="30" LOG_CI_END="0.1302567144921877" LOG_CI_START="-0.5930448495373613" LOG_EFFECT_SIZE="-0.2313940675225867" MODIFIED="2010-02-12 06:08:10 -0500" MODIFIED_BY="Cathy Bennett" ORDER="696" O_E="0.0" SE="0.4248709191114429" STUDY_ID="STD-Cohen-1999" TOTAL_1="50" TOTAL_2="45" VAR="0.18051529790660226" WEIGHT="20.80224844174886"/>
<DICH_DATA CI_END="0.5591808294227578" CI_START="0.0069856650916170025" EFFECT_SIZE="0.0625" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="-0.2524477260653533" LOG_CI_START="-2.1557922392464963" LOG_EFFECT_SIZE="-1.2041199826559248" MODIFIED="2010-02-12 06:07:50 -0500" MODIFIED_BY="Cathy Bennett" ORDER="697" O_E="0.0" SE="1.118033988749895" STUDY_ID="STD-Cucchiara-1987" TOTAL_1="10" TOTAL_2="10" VAR="1.25" WEIGHT="10.909056005257646"/>
<DICH_DATA CI_END="0.08990325187735904" CI_START="2.895425910396616E-4" EFFECT_SIZE="0.00510204081632653" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="14" LOG_CI_END="-1.0462245991805532" LOG_CI_START="-3.5382875435323995" LOG_EFFECT_SIZE="-2.292256071356476" ORDER="698" O_E="0.0" SE="1.4638501094227998" STUDY_ID="STD-Escobar-Castro-1994" TOTAL_1="15" TOTAL_2="15" VAR="2.142857142857143" WEIGHT="7.808696162087145"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-12 06:08:09 -0500" MODIFIED_BY="Cathy Bennett" ORDER="81" O_E="0.0" SE="0.0" STUDY_ID="STD-Moya-1999" TOTAL_1="6" TOTAL_2="6" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.2917016543173256" CI_START="0.12839208622867962" EFFECT_SIZE="0.4072398190045249" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="17" LOG_CI_END="0.11116221579066045" LOG_CI_START="-0.8914617442822321" LOG_EFFECT_SIZE="-0.39014976424578585" MODIFIED="2010-02-12 06:08:06 -0500" MODIFIED_BY="Cathy Bennett" ORDER="699" O_E="0.0" SE="0.5889462772154628" STUDY_ID="STD-Scott-1997" TOTAL_1="23" TOTAL_2="26" VAR="0.34685771744595273" WEIGHT="18.23077079297693"/>
<DICH_DATA CI_END="4.005669527767448" CI_START="0.07101046216435611" EFFECT_SIZE="0.5333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6026751166532062" LOG_CI_START="-1.1486776607806815" LOG_EFFECT_SIZE="-0.27300127206373764" ORDER="700" O_E="0.0" SE="1.028753290800731" STUDY_ID="STD-Van-Eygen-1989_x0028_a_x0029_" TOTAL_1="12" TOTAL_2="11" VAR="1.0583333333333333" WEIGHT="11.925477826843533"/>
<DICH_DATA CI_END="0.33271646918312875" CI_START="0.007904173755364825" EFFECT_SIZE="0.05128205128205128" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="13" LOG_CI_END="-0.4779257013904783" LOG_CI_START="-2.102143521334558" LOG_EFFECT_SIZE="-1.290034611362518" ORDER="701" O_E="0.0" SE="0.9540735874430286" STUDY_ID="STD-Van-Eygen-1989_x0028_b_x0029_" TOTAL_1="14" TOTAL_2="17" VAR="0.9102564102564104" WEIGHT="12.850489633876943"/>
<DICH_DATA CI_END="1.5827376296340077" CI_START="0.13054063186436707" EFFECT_SIZE="0.45454545454545453" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.19940892784652764" LOG_CI_START="-0.88425428949094" LOG_EFFECT_SIZE="-0.3424226808222063" ORDER="702" O_E="0.0" SE="0.6365491380834674" STUDY_ID="STD-Vandenplas-1991" TOTAL_1="21" TOTAL_2="21" VAR="0.4051948051948052" WEIGHT="17.473261137208944"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="35.41254771850042" CI_END="2.6472145558111686" CI_START="0.1844807075581029" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="OR" EFFECT_SIZE="0.6988275998514608" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="64" I2="83.05685304628493" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.42278914214329355" LOG_CI_START="-0.7340490443512495" LOG_EFFECT_SIZE="-0.15562995110397795" METHOD="MH" NO="2" P_CHI2="3.58466108119071E-6" P_Q="0.0" P_Z="0.5979508123800115" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="2.559833502702829" TOTALS="YES" TOTAL_1="145" TOTAL_2="145" WEIGHT="100.00000000000001" Z="0.527349637383301">
<NAME>Worst case scenario</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="17.652576121390013" CI_START="2.8483656657121337" EFFECT_SIZE="7.090909090909091" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="15" LOG_CI_END="1.2468080929343206" LOG_CI_START="0.45459574213018994" LOG_EFFECT_SIZE="0.8507019175322553" ORDER="703" O_E="0.0" SE="0.46534945637672825" STUDY_ID="STD-Cohen-1999" TOTAL_1="50" TOTAL_2="45" VAR="0.21655011655011652" WEIGHT="16.631865436444237"/>
<DICH_DATA CI_END="1.8207143386355928" CI_START="0.0448355084205018" EFFECT_SIZE="0.2857142857142857" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.26024181241433425" LOG_CI_START="-1.3483779011148855" LOG_EFFECT_SIZE="-0.5440680443502757" ORDER="704" O_E="0.0" SE="0.944911182523068" STUDY_ID="STD-Cucchiara-1987" TOTAL_1="10" TOTAL_2="10" VAR="0.8928571428571428" WEIGHT="13.374044620749372"/>
<DICH_DATA CI_END="0.13608194333968607" CI_START="8.873944591985204E-4" EFFECT_SIZE="0.01098901098901099" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="14" LOG_CI_END="-0.8661994973402567" LOG_CI_START="-3.05188328730193" LOG_EFFECT_SIZE="-1.9590413923210936" ORDER="705" O_E="0.0" SE="1.2838814775327387" STUDY_ID="STD-Escobar-Castro-1994" TOTAL_1="15" TOTAL_2="15" VAR="1.6483516483516483" WEIGHT="10.973005487601283"/>
<DICH_DATA CI_END="9.750382661996733" CI_START="0.8992212954845389" EFFECT_SIZE="2.961038961038961" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" LOG_CI_END="0.9890216602864833" LOG_CI_START="-0.046133416630539534" LOG_EFFECT_SIZE="0.4714441218279719" ORDER="706" O_E="0.0" SE="0.6080552162813304" STUDY_ID="STD-Scott-1997" TOTAL_1="23" TOTAL_2="26" VAR="0.3697311460469355" WEIGHT="15.762218722522302"/>
<DICH_DATA CI_END="4.005669527767448" CI_START="0.07101046216435611" EFFECT_SIZE="0.5333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6026751166532062" LOG_CI_START="-1.1486776607806815" LOG_EFFECT_SIZE="-0.27300127206373764" ORDER="707" O_E="0.0" SE="1.028753290800731" STUDY_ID="STD-Van-Eygen-1989_x0028_a_x0029_" TOTAL_1="12" TOTAL_2="11" VAR="1.0583333333333333" WEIGHT="12.762385165729683"/>
<DICH_DATA CI_END="4.490413498703385" CI_START="0.2556466534774458" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.6522863347531226" LOG_CI_START="-0.5923598879982361" LOG_EFFECT_SIZE="0.029963223377443202" ORDER="708" O_E="0.0" SE="0.7311113523423156" STUDY_ID="STD-Van-Eygen-1989_x0028_b_x0029_" TOTAL_1="14" TOTAL_2="17" VAR="0.5345238095238095" WEIGHT="14.922788190267323"/>
<DICH_DATA CI_END="1.5827376296340077" CI_START="0.13054063186436707" EFFECT_SIZE="0.45454545454545453" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.19940892784652764" LOG_CI_START="-0.88425428949094" LOG_EFFECT_SIZE="-0.3424226808222063" ORDER="709" O_E="0.0" SE="0.6365491380834674" STUDY_ID="STD-Vandenplas-1991" TOTAL_1="21" TOTAL_2="21" VAR="0.4051948051948052" WEIGHT="15.57369237668581"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.6930943890334293" CI_END="0.43545203061983695" CI_START="0.0804938614111938" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="0.18721969822627127" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="70" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="-0.36105967988602017" LOG_CI_START="-1.0942372383513563" LOG_EFFECT_SIZE="-0.7276484591186883" METHOD="MH" MODIFIED="2010-02-12 06:18:54 -0500" MODIFIED_BY="Cathy Bennett" NO="3" P_CHI2="0.44913118739240554" P_Q="0.0" P_Z="1.0009285611962046E-4" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="89" TOTAL_2="79" WEIGHT="100.0" Z="3.890366683519058">
<NAME>Change in outcome definition: 'any symptoms' vs 'no symptoms' at end of treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5204891755413765" CI_START="0.010276298083106487" EFFECT_SIZE="0.125" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.18198333272126696" LOG_CI_START="-1.9881633067051538" LOG_EFFECT_SIZE="-0.9030899869919435" MODIFIED="2010-02-12 06:18:54 -0500" MODIFIED_BY="Cathy Bennett" ORDER="87" O_E="0.0" SE="1.2747548783981961" STUDY_ID="STD-Cucchiara-1987" TOTAL_1="8" TOTAL_2="9" VAR="1.625" WEIGHT="11.414060374564068"/>
<DICH_DATA CI_END="0.7006348782104852" CI_START="0.007282025167456436" EFFECT_SIZE="0.07142857142857142" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="14" LOG_CI_END="-0.1545082469250914" LOG_CI_START="-2.137747824431385" LOG_EFFECT_SIZE="-1.1461280356782382" MODIFIED="2010-02-12 06:08:48 -0500" MODIFIED_BY="Cathy Bennett" ORDER="710" O_E="0.0" SE="1.164964745021435" STUDY_ID="STD-Escobar-Castro-1994" TOTAL_1="14" TOTAL_2="15" VAR="1.3571428571428572" WEIGHT="13.666835448491186"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-12 06:08:48 -0500" MODIFIED_BY="Cathy Bennett" ORDER="82" O_E="0.0" SE="0.0" STUDY_ID="STD-Moya-1999" TOTAL_1="6" TOTAL_2="6" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.5404439837624991" CI_START="0.004625826311536181" EFFECT_SIZE="0.05" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="-0.2672493133731267" LOG_CI_START="-2.3348106779548354" LOG_EFFECT_SIZE="-1.3010299956639813" MODIFIED="2010-02-12 06:08:45 -0500" MODIFIED_BY="Cathy Bennett" ORDER="711" O_E="0.0" SE="1.2144957801491119" STUDY_ID="STD-Van-Eygen-1989_x0028_a_x0029_" TOTAL_1="12" TOTAL_2="11" VAR="1.475" WEIGHT="12.574812277062108"/>
<DICH_DATA CI_END="0.9138887178451232" CI_START="0.050245031424844176" EFFECT_SIZE="0.21428571428571427" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" LOG_CI_END="-0.03910668410002849" LOG_CI_START="-1.2989068778171227" LOG_EFFECT_SIZE="-0.6690067809585756" MODIFIED="2010-02-12 06:08:46 -0500" MODIFIED_BY="Cathy Bennett" ORDER="712" O_E="0.0" SE="0.7400128699009548" STUDY_ID="STD-Van-Eygen-1989_x0028_b_x0029_" TOTAL_1="28" TOTAL_2="17" VAR="0.5476190476190476" WEIGHT="33.86998350278251"/>
<DICH_DATA CI_END="2.594132441154513" CI_START="0.10964916051774638" EFFECT_SIZE="0.5333333333333333" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="18" LOG_CI_END="0.4139921448376062" LOG_CI_START="-0.9599946889650816" LOG_EFFECT_SIZE="-0.27300127206373764" MODIFIED="2010-02-12 06:01:33 -0500" MODIFIED_BY="Cathy Bennett" ORDER="713" O_E="0.0" SE="0.8070866675202167" STUDY_ID="STD-Vandenplas-1991" TOTAL_1="21" TOTAL_2="21" VAR="0.6513888888888888" WEIGHT="28.47430839710013"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2010-03-02 06:32:35 -0500" MODIFIED_BY="Cathy Bennett">
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2010-02-12 07:09:51 -0500" MODIFIED_BY="Cathy Bennett" NO="1" REF_ID="CMP-001.01" SETTINGS="SHOW_CI_LINES:YES;SHOW_STUDY_NAMES:NO;SHOW_EFFECT_ESTIMATE:YES;DISTINGUISH_SUBGROUPS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 Main analysis for cisapride versus no treatment, outcome: 1.1 'Worse, same or slight improvement' versus 'moderate or excellent improvement'.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2010-03-02 06:32:35 -0500" MODIFIED_BY="Cathy Bennett" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAOgAAAIWCAIAAADSzFZvAAATvUlEQVR42u3dv47c1hXH8QHcpNhC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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2009-10-23 09:17:54 -0400" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2009-10-23 09:17:54 -0400" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-06-10 08:44:06 -0400" MODIFIED_BY="Cathy Bennett">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-10-23 09:17:54 -0400" MODIFIED_BY="[Empty name]">
<P>1. randomised controlled trial.pt.<BR/>2. controlled clinical trial.pt.<BR/>3. randomized.ab.<BR/>4. placebo.ab.<BR/>5. drug therapy.fs.<BR/>6. randomly.ab.<BR/>7. trial.ab.<BR/>8. groups.ab.<BR/>9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8<BR/>10. humans.sh.<BR/>11. 9 and 10<BR/>12. exp esophageal motility disorders/<BR/>13. exp esophagitis/<BR/>14. esophagitis.tw.<BR/>15. oesophagitis.tw.<BR/>16. exp gastroesophageal reflux/<BR/>17. (gastro?esophageal adj5 reflux).tw.<BR/>18. (gastro esophageal adj5 reflux).tw.<BR/>19. (gastro oesophageal adj5 reflux).tw.<BR/>20. infantile reflux.tw.<BR/>21. regurgitat$.tw.<BR/>22. GORD.tw.<BR/>23. GERD.tw.<BR/>24. GER.tw.<BR/>25. exp proton pump inhibitors/<BR/>26. (proton adj3 pump adj3 inhibitor$).tw.<BR/>27. PPI$.tw.<BR/>28. exp omeprazole/<BR/>29. omeprazole.tw.<BR/>30. (lansoprazole or lanzoprazole).tw.<BR/>31. pantoprazole.tw.<BR/>32. rabeprazole.tw.<BR/>33. exp Histamine h2 antagonists/<BR/>34. h2 receptor antagonist$.tw.<BR/>35. exp cimetidine/<BR/>36. exp ranitidine/<BR/>37. exp famotidine/<BR/>38. exp nizatidine/<BR/>39. cimetidine.tw.<BR/>40. ranitidine.tw.<BR/>41. famotidine.tw.<BR/>42. nizatidine.tw.<BR/>43. (prokinetic or prokinetics).tw.<BR/>44. metoclopramide.tw.<BR/>45. exp metoclopramide/<BR/>46. domperidone.tw.<BR/>47. exp domperidone/<BR/>48. bethanechol.tw.<BR/>49. exp bethanechol/<BR/>50. exp cisapride/<BR/>51. cisapride.tw.<BR/>52. (Acenalin or Alimix or Arcasin or Cisaprid or Prepulsid or Propulsid or Propulsin or Propulsit or R 51 619 or R 51,619 or R 51619 or R51619 or Risamol).tw.<BR/>53. or/12-24<BR/>54. or/25-49<BR/>55. 53 or 54<BR/>56. or/50-52<BR/>57. 55 and 56<BR/>58. exp infant, newborn/<BR/>59. exp infant/<BR/>60. exp child/<BR/>61. exp adolescent/<BR/>62. infan$.tw.<BR/>63. child$.tw.<BR/>64. neonat$.tw.<BR/>65. newborn$.tw.<BR/>66. pediatric$.tw.<BR/>67. paediatric$.tw.<BR/>68. juvenile$.tw.<BR/>69. (young adj3 people).tw.<BR/>70. youth$.tw.<BR/>71. adolescen$.tw.<BR/>72. or/58-71<BR/>73. 57 and 72<BR/>74. 11 and 73<BR/>75. limit 74 to yr="2005-2009"<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>